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La voie de conversion de Big ET-1 en ET-1, chymase dépendante a été établie in vitro. Ce n'est que 
récemment, en 2009 que notre groupe a démontré que la conversion de Big ET-1 en ET-1 (1-31) peut 
avoir lieu in vivo chez la souris (Simard et al., 2009), sachant que ET-1 (1-31) est convertie en ET-1 
via NEP in vivo (Fecteau et al., 2005). En plus, en 2013, notre laboratoire a démontré que la mMCP-
4, l'analogue murin de la chymase humaine, produit l'ET-1 (1-31) à partir du précurseur Big ET-1 
(Houde et al., 2013). Jusqu'a présent, dans la littérature, on ne trouve pas de caractérisations 
spécifiques de chymases (humaine ou murine) recombinantes. En fait, le groupe de Murakami, en 
1995, a publié une étude caractérisant, d'une façon chymostatin dépendante, la CMA1 (chymase 
humaine) en utilisant l'Angiotensine I comme substrat (Murakami et al., 1995). Cependant, le 
chymostatin est un inhibiteur non-spécifique de la chymase. Il a été démontré que le chymostatin 
peut inhiber l'élastase, une enzyme pouvant convertir l'Angiotensine I en Angiotensine II (Becari et 
al., 2005). Basé sur ces observations, l'hypothèse formulée dans la présente étude est que la CMA1 
recombinante ou extraite des cellules LUVA (lignée humaine de mastocytes) ou des fractions 
solubles des aortes humaines convertit la Big ET-1 en ET-1 (1-31) d'une façon TY-51469 (un 
inhibiteur spécifique de la chymase) sensible. Dans un deuxième volet, on a étudié la cinétique 
enzymatique de CMA1 en vers le substrat Big ET-1 et Ang I. L’affinité de CMA1 contre la Big ET-1 
était plus grande comparé à l’Ang I (KM Big ET-1 : 12.55 μM et Ang I : 37.53 μM). Cependant 
CMA1 était plus efficace dans le clivage de l’Ang I comparé à la Big ET-1 (Kcat/KM Big ET-1 : 6.57 
x 10-5 μM-1.s-1 et Ang I : 1.8 x 10-4 μM-1.s-1). Dans un troisième volet impliquant des expériences in 
vivo, l’effet presseur de la Big ET-1, l’ET-1 et l’Ang I a été testé chez des souris conscientes mMCP-
4 KO comparé à des souris de type sauvage. L’augmentation de la pression artérielle moyenne a été 
plus importante chez les souris de type sauvage après l’administration de Big ET-1 que chez les 
souris mMCP-4 KO. Cet effet n’a pas été observé après l’administration d’ET-1 et/ou d’Ang I ce qui 
explique le rôle de la chymase dans l’effet de la conversion de Big ET-1 en ET-1 (1-31). 
 
Mots clés : Chymase, Enzymes recombinantes, Spectrométrie de masse, radio-télémétrie, analyse in 
silico 
  
  
ABSTRACT 
Role of human chymase (CMA 1) in the conversion of big-endothelin-1 to endothelin-1 (1-31) 
by 
Walid Semaan 
Program of Pharmacology 
Thesis submitted to the Faculty of Medicine and Health Sciences for Masters of Science (M.Sc.) in 
Pharmacology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, 
Quebec, Canada, J1H 5N4 
The chymase-dependant pathway responsible for converting Big ET-1 to ET-1 was established in 
vitro. It has only been recently, in 2009, that our group demonstrated that the conversion of Big ET-1 
to ET-1 (1-31) can occur in vivo in mice (Simard et al., 2009), knowing that ET-1 (1-31) is converted 
to ET-1 via NEP in vivo (Fecteau et al., 2005). In addition, our laboratory demonstrated in 2013 that 
mMCP-4, the murine analogue of human chymase, produces ET-1 (1-31) from the Big ET-1 
precursor (Houde et al. 2013). 
Thus far, in the literature, there are no specific characterizations of recombinant chymases (human or 
murine). In fact, the group of Murakami published in 1995 a study characterizing the CMA1 (human 
chymase) in a chymostatin-dependent fashion, using Angiotensin I as a substrate (Murakami et al., 
1995). However, chymostatin is a non-specific inhibitor of chymase. It has been shown that 
chymostatin can inhibit elastase, an enzyme that can convert Angiotensin I to Angiotensin II (Becari 
et al., 2005). 
Based on these observations, the proposed hypothesis in the present study suggests that recombinant 
as well as extracted CMA1 from LUVA (human mast cell line), in addition to soluble fractions of 
human aortas, convert Big ET-1 into ET-1 (1-31 ) in a TY-51469 (a chymase-specific inhibitor) 
sensitive manner. 
In a second component, we studied the enzyme kinetics of CMA1 with regard to the Big ET-1 and 
Ang I substrate. The affinity of CMA1 against Big ET-1 was greater compared to Ang I (KM Big 
ET- 1: 12.55 μM and Ang I: 37.53 μM). However, CMA1 was more effective in cleaving Ang I 
compared to Big ET-1 (Kcat / KM Big ET-1: 6.57 x 10-5 μM-1.s-1 and Ang I: 1.8 x 10-4 ΜM-1.s-
1). 
In a third component involving in vivo experiments, the pressor effects of Big ET-1, ET-1 and Ang I 
were tested in conscious mMCP-4 KO mice compared to wild-type mice. The increase in mean 
arterial pressure after administration of Big ET-1 was greater in wild-type mice compared to mMCP-
4 KO mice. This effect was not observed after administration of ET-1 and / or Ang I. 
 
Key words: Chymase, Recombinant enzymes, Mass spectrometry, radio-telemetry, in silico analysis 
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I- INTRODUCTION 
 
1.1 Mast cells development 
Mast Cells (MC) are immune cells maturing from Mast cell-committed progenitor (MCcP) and 
originating from hematopoietic progenitors in the bone marrow .The multipotent hematopoietic 
progenitor stem cells (MPP) develop into common myeloid progenitor (CMP) and common 
lymphoid progenitor (CLP) (Kondo et al., 1997; Akashi et al., 2000).CMP will further divide 
into Megakaryocyte/Erythrocyte progenitor (MEP) and Granulocyte/Monocyte progenitor 
(GMP).The lineage origin of Mast cell-committed progenitor was a debate since the literature 
shows conflicting data. It was known for a certain time that they belong to the CMP/GMP 
lineage (Suda et al., 1983). However in 2005, Chen and collaborators concluded that it could be 
directly derived from MPP. On the other hand, Franco and collaborators found that MCcP are 
closer to the MEP lineage relying on gene expression profiling of cells (Franco et al., 2010). In 
contrast, Arinobu and colleagues verified that MCcP belonged to GMP lineage (Arinobu et al., 
2005). Moreover, Bipotent Basophil/Mast cell progenitors (BMCP) were identified in the spleen 
of C57BL mice (Arinobu, 2005; Iwasaki, 2006; Qi et al., 2013); these progenitors were isolated 
and were capable of developing basophils and MC within the GMP fraction in the bone marrow 
(Qi et al., 2013). When put together, the data suggests that within the GMP pathway, bipotent 
progenitors give rise to the MCcP. These MCcP circulate in the blood and are home to tissues 
where they will mature into MC. MCcP express several markers and receptor such as CD34, 
CD13, c-kit, stem cell factor (SCF) and the IgE receptor FcƐRI just like the mature MC; however 
they are less granulated than MC. Homing of the MCcP is triggered by several cytokines and 
mediator such as IL-3 and SCF (Kawakami and Galli, 2002). 
 
The maturation of MCcP give rise to two types of MC, the MCT and MCTC depending on the 
type of tissue they are maturing in (Irani et al., 1986; Kitamura et al., 1989; Metcalfe et al., 
1997; Kawakami and Galli, 2002). The MCT are present essentially in the mucosa of the 
gastrointestinal tract and the bronchi. Their granules contain mostly Tryptase. On the other hand, 
the MCTC are present in the skin, lymph nodes and submucosa of the gastrointestinal tract. Their 
granules contain Tryptase and Chymase (Irani et al., 1986; Irani et al., 1989; Kitamura et al., 
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1989; Metcalfe et al., 1997). It has been shown that MCTC are similar to murine connective 
tissue MC while MCT resemble mucosal MC. (Miyazaki et al., 2006; Pejler et al., 2010). 
 
1.2 Mast Cell dependent diseases 
MC have been known for their role in allergy (Williams and Galli,2000). Once activated, by 
Immunoglobulin E (IgE) binding on their Fcε receptor, they will degranulate and thus release 
hormonal mediators and proteases, triggering an allergic reaction and resulting in sustained 
inflammation (Galli,1993; He and Shi, 2013). 
In addition to their pivotal role in allergy, mast cells are key players in mediating the immune 
response. Due to their Fcγ receptors I and III and toll-like receptors (TLR) types 2 and 4, they 
sense the microenvironment thus guiding the innate and acquired immunity (Frossi et al., 2004; 
Mekori et al., 2000; Okumura et al., 2003). For example, MC-deficient mice are not protected 
against sepsis secondary to bacterial peritoneal infection (Schneider et al., 2007). Given this role, 
their implication in inflammatory, immune and autoimmune diseases becomes consequential. It 
has, for example been shown that MC have an involvement in Rheumatoid arthritis, 
inflammatory bowel disease, metabolic diseases, atopic dermatitis, idiopathic pulmonary 
fibrosis, liver fibrosis and psoriasis.  
In addition, their function is becoming clearer in neoplasms such as gynecological neoplasms 
and prostate cancer. MC are associated with tumor progression and cancer cells invasion in 
prostate cancer (Li et al., 2015; Johansson et al., 2010). Moreover, new studies are presenting 
MC as a target for immunotherapy in prostate cancer (Olford and Marshall, 2014).  Furthermore, 
their implication in vascular and cardiovascular diseases is of significant importance especially 
regarding atherosclerosis, plaque erosion and abdominal aortic aneurysms (AAA) (Bot et al., 
2008; Bot and Biessen, 2011). 
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1.3 Mast Cells in Cardiovascular diseases 
 
In the 1950’s, MC were thought to have a protective role in atherosclerosis (Constantinides, 
1953; Cairns and Constantinides, 1954) since their number was found to be inversely correlated 
with the disease. Myocardial tissue from atherosclerotic patients showed a reduced number of 
mast cells compared to healthy subjects (Constantinides, 1953; Cairns and Constantinides, 1954). 
However in the following years the tendency shifted more towards the proatherogenic function 
of Mast cells. Later studies showed that the number of MC increased in the intima and adventitia 
of atherosclerotic plaques with the progression of the disease. (Laine et al., 1999; Kaartinen et 
al., 1994a; 1994b; Kovanen et al., 1995). These results were further confirmed to be true in 
human aorta, coronary arteries and carotid arteries (Atkinson et al., 1994; Jeziorska et al., 1997). 
Both types of Mast cells were found to be present in the plaque the MCTand MCTC (Kaartinen 
et al., 1994b). In addition, Mast cell granules were found to be ingested by foam cells and 
smooth muscle cells suggesting a role for MC in plaque expansion (Kaartinen et al., 1995). 
Furthermore, some studies showed that MC expressing bFGF an angiogenic factor, were co-
localized along with intraplaque neovessels. Indeed, the group of Kaartinen hypothesized in 1995 
that with the release of histamine, the neovessels could bleed causing intraplaque hemorrhage 
and therefore plaque destabilization (Kamat et al., 1987Kaartinen et al., 1995; Lappalainen et al., 
2004). 
 
1.4 Mast Cell Proteases 
 
 The numerous physiological and pathological roles of MC are suggested to be dependent on 
their granule content. The MC degranulation can be initiated by various stimuli such as Fc 
receptor mediated activation- in allergic reactions- (Genovese et al., 2000), complement receptor 
mediated activation (Nilsson et al., 1996) or Toll-like receptor activation. MC activation 
enhances de novo synthesis of cytokines, prostaglandins (PGE2, PGD2) and Leukotrienes (Galli 
et al., 2005). Once degranulated, MC release several mediators such as histamine (known role in 
allergies), proteases and cytokines. 
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MC granules contain several proteases such as matrix metalloproteases (MMPs) (Baram et al., 
2001), cathepsin D, C, and E (Dragonetti et al., 2000;Henningsson et al., 2005;Wolters et al., 
2000), Chymase, Tryptase and Carboxypeptidase A (MC-CPA); of which the last three are 
known to be MC-specific. Tryptases and chymases belong to theserine protease class, while MC-
CPA is a zinc-dependent metalloprotease. These proteases have different substrate specificities. 
Tryptases have a Trypsin-like activity; Chymases have a Chymotrypsin like activity; whereas 
MC-CPA cleave at the C-terminal of peptides.  It is believed that these MC proteases, especially 
the chymases and tryptases are at the basis of the role of MC in cardiovascular and metabolic 
diseases (Sun et al., 2011; Yang et al., 2008; Lutgens et al., 2006). 
 
1.5 Chymase Synthesis 
The chymase, a mast cell protease found in the granules, is synthesized as a preproenzyme. The 
preproenzyme has a signal on its N terminal responsible for the guidance of the peptide to the 
endoplasmic reticulum lumen (for review see Nakano et al., 1997; Watts et al., 2007; Pejler et 
al., 2010 and Takai et al., 2010). Although there is no consensus regarding the biosynthesis of 
the active chymase from prepro-chymase (Nakano et al., 1997; Watts et al., 2007; Pejler et al., 
2010 and Takai et al., 2010), it is postulated that this signal peptide is 2 amino acids (aa) long. 
Once cleaved, the preproenzyme will give rise to a proenzyme that will also be cleaved on the N-
terminal site leading to the active enzyme. It is noteworthy that the active enzyme itself is stored 
in the granules unlike other known zymogens. The prochymase is constituted of 226 aa. An 
additional 2 aa on the N-terminal will be cleaved (from the prochymase) to lead to the active 
chymase (Caughey et al., 1991; Huang et al., 1991; Serafin et al., 1991; Urata et al., 1991). 
Dypeptidyl Peptidase I (DPPI) or cathepsin C is believed to be the enzyme responsible for this 
cleavage. A paramount role for heparin has been demonstrated in this cleavage (Murakami et al., 
1995; McEuen et al., 1998).The N-terminal of the proenzyme is attached to a region on the 
proenzyme which makes it inaccessible for cleavage by DPPI. Heparin will cause a 
conformational change in the prochymase, by binding to a heparin binding site on the 
proenzyme, exposing the N-terminal to DPPI. The cleavage can thus occur and activation of the 
enzyme takes place (Murakami et al., 1995; McEuen et al., 1998). In a DPPI Knockout (KO) 
mouse model, there was a failure in generating active chymase in connective tissue MC, 
5 
 
demonstrating further the importance of DPPI in the synthesis of active chymase (Wolters et al., 
2001). 
 
Once liberated from the granules, the active chymase will be bound to the extracellular matrix 
(ECM). In the ECM, endogenous chymase inhibitors (such as α1-antitrypsin, α2 
antichymotrypsin, α 2-macroglobulin, and eglin C) block the activity of the chymase. However, 
the fact that it will be bound to heparin renders it resistant to the endogenous inhibitors and 
preserves its activity for several weeks (Lindstedt et al., 2001). 
 
In Humans, a single chymase has been identified to date, the CMA1. Despite the fact that it is an 
α-chymase, it shows similarities in proteolytic activities to the mouse mast cell protease 4 
(mMCP-4) which is a β-chymase present in murine connective tissue MC (Wu et al., 2005; 
Andersson et al., 2008; Urata et al., 1990). 
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Figure1. Structure of CMA1: CMA1 and PMSF-bound inhibitor (in grey)- complex. Catalytic 
residues are shown in ball-and-stick representation: His66 in purple, Asp110 in pink and Ser203 
in orange. α-helices are shown in red and β-pleated sheets are shown in green. (MEROPS 
database) 
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1.6 Chymase substrates 
Chymase plays an important role in physiology and pathophysiology. This role is attained due to 
its broad cleavage specificity which explains its ability to process a large number of 
proteins/peptides. In table I, some chymase substrates are listed. It is important to note that some 
of these substrates were identified in vitro either by direct incubation or by the use of chymase 
inhibitors; other substrates were identified in vivo in mice models with chymase Knock-out (KO) 
genes. 
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Table I. Chymase substrates modified from Pejler et al. 2007 
 
Substrates Chymase activity References 
Procollagen Activation Kofford et al., 1997 
Procollagenase Activation Saarinen et al., 1994 
Pro-MMP-9 Activation Chen et al., 2002; 
Tchougounova et al., 2005 
Fibronectin Degradation Lazaar et al., 2002 ; 
Tchougounova et al.,2003 
Vitronectin Degradation Banovac et al., 1993 
TIMP-1 Inactivation Frank et al., 2001 
Substance P 
 
Degradation Caughey et al., 1988 
VIP Degradation Caughey et al., 1988 
Bradykinin 
 
Inactivation Reilly et al., 1985 
Kallidin 
 
Inactivation Reilly et al., 1985 
Big-endothelin 1/2 Cleavage Kido et al., 1998; Nakano et 
al., 1997;Takai et al., 1998 
Neurotensin 
 
Hydrolysation Goldstein et al., 1991 
Hepatocyte growth factor 
 
Inactivation Raymond et al., 2006 
 
CTAP-III Activation Schiemann et al., 2006 
Pro-IL-18 Activation Omoto et al., 2006 
IL-6, IL-13 
 
Degradation Zhao et al., 2005 
TGF-β1 
 
Activation Taipale et al., 1995 
SCF Liberation de Paulis et al., 1999; 
Longley et al.,1997 
apoE, apoA-I, apoA-II 
 
Degradation Lee et al., 2002b, 2003a; 
Lindstedt et al., 1996 
apoB 
 
Degradation Kokkonen et al., 1986 
 
Phospholipid transfer protein Degradation Lee et al., 2003b 
PAR-1 
 
Activation Schechter et al., 1998 
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Table I. Chymase substrates modified from Pejler et al. 2007 continued 
 
Substrates Chymase activity References 
C3a Degradation Gervasoni et al., 1986; 
Kajita and Hugli, 1991 
Albumin Degradation Raymond et al., 2003 
 
Occludin Degradation Scudamore et al., 1998 
C1 inhibitor Inactivation Schoenberger et al., 1989 
Ang I Processing and cleavage Urata et al., 1990 
Thrombin Inactivation Pejler and Karlstrom, 1993 
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1.7 The Role of Chymase in Physiology and Pathophysiology 
1.7.1 Chymase in wound healing 
Wound healing comprises three major stages: the inflammatory phase, the proliferative phase 
and the remodeling phase (Schilling 1976). Chymase has a role in all stages. It has a paramount 
role in ECM regulation in direct and indirect ways which is a key step in the inflammatory phase 
of wound healing (Nishikori et al., 1998; Noli and Miolo 2001, 2010; Younan et al., 2010). This 
is expected given the abundance of CTMC in the connective tissue (Irani et al., 1986; Kitamura 
et al., 1989; Metcalfe et al., 1997; Kawakami et al., 2002). Chymase is responsible for the 
degradation of fibronectin and Vitronectin, both of which are components of the ECM (Lazaar et 
al., 2002; Tchougounova et al., 2003; Banovac et al., 1993). 
On the other hand, in the proliferative and remodeling phases, chymase stimulates fibroblasts by 
releasing TGF-β1 causing ECM deposition (Lindstedt et al., 2001). In addition, chymase was 
shown to contribute to angiogenesis and vascular growth, in granulation tissue (Norrby et al., 
1986). Furthermore, chymase was demonstrated to cleave precollagen leading to fibril formation 
(Kofford et al., 1997). 
 
1.7.2 Chymase in cardiovascular diseases and Atherosclerosis 
Atherosclerosis is an inflammatory disease of the arteries. As we have mentioned earlier, MC 
have been shown to be involved in this disease. More evidence has demonstrated a role for 
chymase in atherosclerosis (Bot et al., 2015). 
Chymase can affect SMC directly and indirectly. It indirectly regulates SMC differentiation, 
migration and proliferation by the activation of TGF-β1 (Otsuka et al., 2006). It can also directly 
induce their apoptosis (Leskinen et al., 2001) which explains the thinning of the aortic wall 
media in atherosclerosis. Chymase can also inhibit collagen synthesis and induce the apoptosis of 
endothelial cells by degrading Vitronectin and Fibronectin of the ECM (Heikkilä et al., 2008) 
and/or via TGF-β1 which will further cause endothelial dysfunction. 
Chymase has also a role in activating the metalloprotease Pro-MMP-9 which has been implicated 
in atherosclerosis (Wågsäter et al., 2011).  
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Within the atheroma, chymase is involved in the proteolysis of LDL, the step preceding foam 
cell formation (Lee et al., 1992). In addition, by degrading ApoE, ApoAI and HDL3, it inhibits 
the efflux of cholesterol from foam cells, the process that will maintain the presence of foam 
cells in atherosclerotic plaques (Lee et al., 1992, 1999, 2002 a, 2002 b; Lindstedt L et al., 1996). 
Finally, higher chymase levels were found in the serum of patients who suffered from a 
myocardial infarction or unstable angina compared to individuals without coronary artery disease 
(Xiang et al., 2011). 
 
1.7.3 Chymase in Metabolic diseases and Diabetes Mellitus 
Mast cells have been shown to be involved in the pathogenesis of metabolic diseases such as 
Obesity, Diabetes Mellitus (DM), type I (DM I) and II (DM II) and in complications of DM. 
Studies have shown that MC are present in a larger amount in white adipose tissue (WAT) of 
obese patients compared to lean subjects (Tanaka et al., 2011; Liu et al., 2009).  
Mast cell deficient mice gained less body weight, had less adipose tissue inflammation and had 
improved glucose intolerance (Liu et al., 2009). 
In a more specific way, chymase has been linked to metabolic diseases and DM. In fact, in a 
hamster model of DM I there was an increase in blood glucose levels, pancreatic chymase and 
Ang II formation; all of which were decreased with the inhibition of chymase by TY-51469 
(Maeda et al., 2010; Takai et al., 2009).  
On the other hand, chymase levels were measured in the blood of patients suffering from pre-
diabetes and DM II and were shown to be higher than chymase levels in the blood of controls 
(with normal blood glucose levels) (Wang et al., 2011). 
 
DM complications, such as nephropathies and retinopathies can be detrimental. Although it has 
not been directly linked to these complications, chymase has been reported to have an 
unfavorable role in these processes. Chymase levels were elevated in diabetic nephropathy. 
These levels were associated with glomerulosclerosis and tubulointerstitial fibrosis (Ritz, 2003) 
and diabetic vascular diseases secondary to Ang II formation (Koka et al., 2006). Furthermore, 
once activated by the chymase, pro-MMP-9 is believed to be active in diabetic nephropathy and 
retinopathy (Van der Zijl et al., 2010; Kowluru et al., 2012). 
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1.8 The role of Chymase in the conversion of Angiotensin I to Angiotensin II  
The role of chymase in Ang II synthesis is well documented (for review see Takai et al., 2010 
and Pejler et al., 2010). As mentioned in table I, Ang I is a substrate for chymase (Urata et al., 
1990). Chymase was found to cleave Ang I and form Ang II. Ang I is a peptide constituted of ten 
aa Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8-His9-Leu10, chymase is responsible for the 
cleavage of the Phe8-His9 bond to form Ang II, an eight aa peptide (Reilly et al., 1982; Urata et 
al., 1990). 
It is well known that Ang II is a product of the activation of the Renin-Angiotensin system 
(RAS). The conventional conversion of Ang I to Ang II is done via Angiotensin converting 
enzyme (ACE). RAS is activated, in normal physiology, when the body senses a decrease in 
blood flow to the kidneys (decreased intratrarenal pressure), which implies a decrease in blood 
pressure. Ang II will be formed and will cause a vasoconstriction leading to restoration of normal 
blood pressure. This is believed to occur in the blood stream. 
However this is not the only pathway, since ACE inhibitors could not inhibit totally the 
production of Ang II (Padmanabhan et al., 1999; Wolny et al., 1997) and in an ACE KO model 
of mice, the formation of Ang II was not totally repressed either (Wei et al., 2002). The 
alternative route, involving the chymase was shown to occur mainly in the tissues (as opposed to 
bloodstream) form Ang II in the tissues where Ang II plays a major role in Pathophysiology. 
 
1.9 The role of Angiotensin II in physiology and Pathophysiology 
As mentioned in the previous paragraph, Ang II plays a key role in physiology and 
Pathophysiology and works on several systems.  
The main system we are interested in here is the cardiovascular system where Ang II can 
stimulate cardiac remodeling and hypertrophy as well as vascular hypertrophy (Humma and 
Terra, 2002; Mehta and Griendling, 2007). It also causes constriction of the resistance vessels 
which will increase the systemic vascular resistance hence increasing the arterial pressure 
(Humma and Terra, 2002). 
Ang II also affects the renal system. It stimulates the release of aldosterone in the adrenal cortex 
causing an increase in sodium reabsorption and water retention; besides the stimulation of 
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Vasopressin or antidiuretic hormone (ADH) release will further increase fluid retention in the 
body (Humma and Terra, 2002). 
On another level, Ang II impacts the nervous system by facilitating Norepinephrine release and 
inhibiting its reuptake on sympathetic synapses (Humma and Terra, 2002). 
 
In more details, Ang II affects all the cells in the cardiovascular system. With excess production 
of Ang II, growth, hypertrophy and migration of vascular smooth muscle cells (VSMC) will take 
place. In addition, endothelial dysfunction will occur and there will be an increase in the 
expression of the adhesion molecules. Moreover, with cardiac remodeling, electrophysiological 
conduction will be altered (Mehta and Griendling, 2007). 
 
These changes in physiology secondary to excess Ang II production implies that this peptide has 
a supreme role in myocardial infarction, arrhythmias, strokes, diabetic vascular diseases and 
congestive heart failure (Schieffer et al., 2000 ; Mehta and Griendling, 2007) 
 
1.10 Angiotensin receptors 
Most physiologic and pathophysiologic effects of Ang II are mediated by its receptor angiotensin 
type 1 receptor (AT1R). Other receptors also exist, such as angiotensin type 2, 3 and 4, however 
our focus will be on AT1R since it is responsible for most of the cardiovascular diseases related 
to the renin-angiotensin system (RAS). AT1R is a seven-membrane G protein-coupled receptor. 
It is composed of 359 aa. The receptor is widely distributed in the body: It is present on tissues of 
the heart, vessels, kidneys, adrenals, liver, lungs and brain (Griendling, Lassegue and Alexander, 
1996). 
 
As shown in Fig. 2, once Ang II binds to AT1R, the Gαq/11 and Gα12/13 protein cascade will be 
activated (Ushio-Fukai et al., 1998). The Gαq/11 will activate the phospholipase C (PLC) which 
will cleave the Phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and 
inositol-1,4,5-triphosphate (IP3). IP3 will increase calcium levels in the cytoplasm by binding to 
its receptor on the sarcoplasmic reticulum and opening a channel facilitating calcium efflux. 
Calcium released from the sarcoplasmic reticulum activates the myosin light chain kinase 
(MLCK) which will phosphorylate the myosin light chain thereby enhancing the interaction 
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between actin and myosin leading to SMC contraction (Yan et al., 2003). On the other hand, 
DAG will activate protein kinase C (PKC) which will phosphorylates the Sodium/Hydrogen 
(Na+/H+) exchange and will act as an effector in the Ras/Raf/MEK/ERK pathway (Yan et al., 
2003).  
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Figure 2 AT1R signaling pathway after activation by Ang II. PLC: Phospholipase C, PIP2: 
Phosphatidylinositol 4,5-bisphosphate, DAG:Diacylglycerol, IP3: Inositol-1,4,5-triphosphate, 
SR: Sarcoplasmic Reticulum, Ca2+: Calcium, CaM: Calmodulin, MLC: Myosin light chain, 
MLCK: Myosin light chain kinase, MLC-P: Phosphorylated myosin light chain, PKC: Protein 
Kinase C. (Modified from Ushio-Fukai et al., 1998) 
 
  
Ca2+ Channel 
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1.11 Endothelin-1 
As mentioned in table I, Big endothelin-1 (Big ET-1) has been shown in vitro to be a substrate 
for the chymase (Kido et al., 1998; Nakano et al., 1997; Takai et al., 1998). The end product of 
the processing and cleavage of the Big ET-1 is endothelin-1 (ET-1).  
ET-1 is a potent vasoconstrictor constituted of 21 aa. It was first isolated in 1988 from porcine 
aortic endothelial cells by Yanagisawa (Yanagisawa et al., 1988). Three isomers of endothelin 
exist ET-1, ET-2 and ET-3 (Inoue et al., 1989). Each peptide is encoded by a different gene. ET-
1 is produced by endothelial cells, mainly the vascular endothelium (Masaki, 2000; Simonson 
and Dunn, 1990). ET-2 is produced by the renal medulla and is implicated mainly in the vascular 
function in the kidneys; ET-3 was found to be present in nerve endings and implicated in 
neurotransmission (Waeber et al., 1990; Spyer et al., 1991). 
 
1.12 The role of Endothelin-1 in Physiology and Pathophysiology 
ET-1 has several important physiologic actions in the embryologic and adult life. In fact, a 
repression of the ET-1 gene in mice caused their deaths from cardiovascular and craniofacial 
anomalies leading to respiratory failure minutes after their delivery (Kurihara et al., 1994; 
Yanagisawa et al., 1998). In addition, ET-1 has a key role in maintaining the basal vascular tone 
(Masaki, 2000).  It is also involved in sodium excretion from the renal tubules (Hirata et al., 
1988, Murray et al., 2008). It is also involved in bronchoconstriction, sputum production and 
MC degranulation (Rubanyi and Polokoff, 1994; Murray et al., 2008). 
On the other hand, ET-1 is involved in several diseases and pathologies. Table II summarizes 
most of them. 
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Table II. Diseases and pathologies which ET-1 is involved in 
 
Conditions References 
Atherosclerosis Attina et al., 2005; Ihling et al., 2001 
HTN Dhaun et al., 2008 
Pulmonary HTN Attina et al., 2005 
Metabolic syndrome Weil et al., 2011 
IBS  
Congestive Heart failure Wei et al., 1994; Kiowski et al., 1995; 
Pacher et al., 1996 
Cancer metastasis Grant et al., 2003; Said and Theodorescu, 
2012 
Pain mediation Hans et al., 2008 
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1.13 Biosynthesis of Endothelin-1 
The first product of the ET-1 gene is Pre-proendothelin, a peptide constituted of 212 aa. This 
peptide will be processed by a carboxypeptidase to form proendothelin which is the precursor of 
the Big ET-1. Furin, an enzyme of the subtilisin family will cleave the proendothelin further to 
generate Big ET-1(Blais et al., 2002; D’Orleans-Juste et al., 2003). 
 
1.14 Classical Pathway 
Big ET-1 is found in the peripheral circulation. It has some vasoconstrictive capacities however 
once converted to ET-1 via the Endothelin Converting Enzyme (ECE), the product, ET-1, has a 
much higher- 140 times higher- vasoconstrictive potency (Rubanyi and Polokoff, 1994). 
 
1.15 Endothelin Converting Enzyme 
The ECE cleaves the bond between Trp 21 and Val 22 of the Big ET-1 to generate ET-
1(McMahon et al., 1991; D'Orleans-Juste et al., 2003). The ECE is a Zinc-dependent 
Metalloendopeptidase localized in several cell types such as endothelial cells, SMC, 
cardiomyocytes and macrophages (Hioki et al., 1991; Hisaki et al., 1993; Takahashi et al., 1995; 
Barnes et al., 1997; Barnes and Turner, 1999; Korth et al., 1999). Three isoforms of ECE have 
been identified, the ECE-1, ECE-2 and ECE-3 (Xu et al., 1994; Shimada et al., 1994 ; Maguire 
et al., 1997; Schweizer et al., 1997; Fukuchi and Giaid, 1998; Kobayashi et al., 1998; Rossi et 
al., 1999). 
ECE-1 and ECE-2 were shown to generate ET-1 from Big ET-1 (Emoto and Yanagisawa, 1995), 
however ECE-1 is believed to be more involved physiologically since ECE-2 maximal activity 
occurs at a more acidic pH (pH= 5.5) (Emoto and Yanagisawa, 1999). Furthermore, ECE-1 binds 
and process several substrates such as bradykinin, substance P, Ang I and insulin, with different 
affinities (Hoang et al., 1997; Johnson et al., 1999).  
Four isoforms of ECE-1 as well as of ECE-2 have been identified: ECE-1a, ECE-1b, ECE-1c 
and ECE-1d; ECE-2a-1, ECE-2a-2, ECE-2b-1 and ECE-2b-2 (Shimada et al., 1995; Schweizer et 
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al., 1997; Valdenaire et al., 1999; Ikeda et al., 2002). The isoforms differ in their N terminal 
sequences which dictate their cellular location. 
 
1.16 Alternative pathway 
The ECE dependent pathway does not seem to be the sole pathway leading to the formation of 
ET-1. It has been shown that in embryos of mice whose ECE-1 and ECE-2 genes were KO, the 
production of ET-1 was not completely inhibited; but was only decreased by 33% (Yanagisawa 
et al., 2000). This suggests that other pathways involved in the production of ET-1 exist, 
independent of ECE. Even though the role of chymase in Ang II biosynthesis is well covered in 
the literature (for review see Takai et al., 2010 and Pejler et al., 2010), less is reported 
concerning the role of chymase in ET-1 synthesis (for review see Nakano et al., 1997 and Watts 
et al., 2007). One of the enzymes able to cleave Big ET-1, as mentioned in table I, is the 
chymase. It has been shown that the latter enzyme can cleave the Big ET-1 at the bond Tyr 31-
Gly 32 leading to an intermediate peptide formed of 31 aa, the ET-1 (1-31). This ET-1 (1-31) 
will be further processed by the neutral endopeptidase (NEP) which cleaves the Trp 21- Val 22 
bond to form ET-1 (Hanson et al., 1997; Nakano et al., 1997); as shown in fig. 3. The NEP is a 
ubiquitous membrane bound metalloendopeptidase responsible not only for the generation of 
ET-1 from ET-1 (1-31) but has a role in the degradation of ET-1 (Vijavaraghavan et al., 1990; 
Turner and Tanzawa, 1997). 
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Figure 3: Schematization of the synthesis of ET-1 via the classical pathway (green arrow) 
and the alternative pathway (blue arrows). (Modified according to Goto et al., 1996, 
Hanson et al., 1997 and Nakano et al., 1997)  
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1.17 Endothelin-1 (1-31) 
There has not been a clear conclusion in the literature on whether ET-1 (1-31) acts directly on 
the endothelin receptors or it has to be cleaved into ET-1 to achieve its activity. Many in vitro 
studies have shown that ET-1 (1-31) can act as an agonist on the endothelin receptors. For 
example, the group of Maguire showed in 2001 that ET-1 (1-31) has vasoconstrictive properties 
when activating the endothelin receptors in a human mammary artery (Maguire et al., 2001). 
Some studies have concluded that ET-1 (1-31) is a selective agonist for one of the endothelin 
receptors, the endothelin A receptor (ETA) (Mazzochi et al., 2000), whereas other studies have 
shown that ET-1 (1-31) is an agonist of both endothelin receptor, ETA and endothelin B (ETB). 
On the other hand, other studies indicated that ET-1 (1-31) needs to be processed by the NEP to 
generate ET-1 which will activate the receptors (Hayasaki-Kajiwara et al., 1999). 
It is important to note that the studies mentioned in the previous paragraph were conducted in 
vitro. A closer look to the studies performed on animals in vivo shows a consensus on the 
necessity of the conversion of the ET-1 (1-31) to ET-1 by the NEP to get its functionality in vivo 
(Fecteau et al., 2005; Simard et al., 2009). 
 
1.18 Endothelin receptors 
There are two known receptors for the endothelin, ETA and ETB. They are G protein coupled 
receptors (GPCR) that have seven transmembrane domains. These receptors are coupled to Gq/11. 
They share about 50 % of identical sequence with the main differences existing in the N-terminal 
(Ogawa et al., 1991; Rubanyi and Polokoff, 1994; Murray et al., 2008). ETA is localized mainly 
on the VSMC whereas ETB is localized on the VSMC along with the endothelial cells (Hosoda et 
al., 1991; Fan et al., 2000; Giannessi et al., 2001). 
 
1.19 ETA receptor 
The binding of ET-1 to ETA will activate the receptor. Similar to the AT1 receptor, stimulation of 
ETA receptor will activate the protein Gq/11 and activate phospholipase C (PLC) which will 
hydrolyze phosphatidylinositol-4,5-bisphosphate (PIP2) into inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG). In addition, activation of both ETA and AT1 receptors induces 
proliferation in non-excitable cells and hypertrophy in excitable cells (Bkaily et al., 2011; 
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Alvarenga et al., 2016). Both types of receptors induce increase of intracellular calcium via 
stimulation of L- and R-type calcium channels as well as release of calcium from the 
endoplasmic reticulum (Bkaily et al., 2005, 2011; Simonson and Dunn, 1990; Giannessi et al., 
2001; Becker et al., 2009). Little is known concerning the differences in signaling and biological 
effects between ETA and AT1 receptors activation. 
 
1.20 ETB receptor 
As mentioned earlier and shown in fig. 4, ETB is present on VSMC and endothelial cells. The 
receptors present on VSMC will activate Gq and Giwill cause an increase in intracellular calcium, 
in a cascade similar to the activation to ETA which will cause a contraction of the VSMC and 
hence a vasoconstriction. However, the activation of ETB present on the endothelial cells will 
cause an increase in Nitric Oxide (NO) and prostacyclin causing a relaxation of the VSMC hence 
a vasodilation (Giannessi et al., 2001; Attina et al., 2005; Murray et al., 2008). 
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Figure 4: ETA and ETB signaling pathway after activation by ET-1. PLC: Phospholipase C, 
PIP2: Phosphatidylinositol 4,5-bisphosphate, DAG:Diacylglycerol, IP3: Inositol-1,4,5-
triphosphate, SR: Sarcoplasmic Reticulum, Ca2+: Calcium, CaM: Calmodulin, MLC: Myosin 
light chain, MLCK: Myosin light chain kinase, MLC-P: Phosphorylated myosin light chain, 
PKC: Protein Kinase C, NO: Nitric Oxide, PI3K: Phosphatidylinositol-4,5-bisphosphate 3-
kinase, PIP3: Phosphatidylinositol (3,4,5)-trisphosphate, eNOS: Endothelial Nitric Oxide 
synthase. (Modified from Ushio-Fukai et al., 1998) 
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1.21 Chymase inhibitors and clinical relevance 
Many chymase inhibitors are currently in clinical trials, some are currently in phase two such as 
SUN 13834 (Ogata et al., 2011). Table III summarizes some of the chymase inhibitors and their 
potential clinical relevance. 
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Table III. Chymase inhibitors and their therapeutic potential 
 
  
 
  
Chymase inhibitors Therapeutic potential Reference 
SUN-C8257 Atherosclerois, pulmonary 
fibrosis, skin disease 
Doggrell, 2008 
SUN13834 Atopic dermatitis Ogata et al., 2011 
BCEAB Cardiac diseases Doggrell, 2008 
Compound 17 Cardiac diseases, asthma Doggrell, 2008 
NK 3201 Cardiac diseases Doggrell, 2008 
TEI-ES48 Cardiac diseases Hoshino et al., 2003 
RO5066852 Atherosclerosis Bot et al., 2011 
JNJ-10311795 Anti-inflammatory De Garavilla et al., 2005 
Suc-Val-Pro-Phe (OPh)2 Cardiac adhesions Soga et al., 2004 
Y-40613 Atopic dermatitis Akahoshi et al., 2001; Imada 
et al., 2002 
TY-51463 Cardiac diseases, liver 
fibrosis, gastroentesitinal 
diseases, diabetes mellitus 
Oyamada et al., 2011; 
Komeda et al., 2010 ; 
Kakimoto et al., 2010 ; Takai 
et al., 2009 
Chymostatin Glaucoma, chorioretinal, 
Gastroentestinal diseases 
Doggrell, 2008; Groschwitz 
et al., 2009 
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1.22 Aim of the study and targeted objectives 
Since the establishment of the chymase dependent route of conversion of Big ET-1, the 
production of ET-1 was not demonstrated to occur in vivo up until recently in 2009, when our 
laboratory has shown that the conversion of Big ET-1 into ET-1 (1-31) occurs in mice (Simard et 
al., 2009); knowing that ET-1 (1-31) is converted to ET-1 via NEP in vivo (Fecteau et al., 2005). 
In addition in 2013, our laboratory has demonstrated that the mMCP-4, which is the murine 
analog of the human chymase, can generate ET-1 (1-31) from the Big ET-1 in vitro and in vivo 
(Houde et al., 2013). However, no information is available concerning the ability of recombinant 
chymases (murine or human) to cleave Big ET-1. In fact the literature shows a chymostatin 
dependent characterization of CMA1 in regards to generation of Ang II from Ang I (Murakami 
et al., 1995). Chymostatin is a general chymotrypsin-like protease inhibitor, not specific to 
chymase. It was shown to inhibit elastase II as well, an enzyme involved as well in the 
production of Ang II from its precursor Ang I (Becari et al., 2005). 
Based on these observations, we hypothesized in this study that the CMA1, whether 
recombinant, extracted from the LUVA cells (human mast cell line) or in the soluble fractions of 
human aortas would generate ET-1 (1-31) from Big ET-1 in a chymase inhibitor - sensitive 
manner. 
In a second aim, we also characterized the kinetic enzymatic activity of CMA1 towards its 
substrate Big ET-1. 
In order to achieve these aims, we propose the following objectives: 
 To validate that the recombinant human chymase (CMA1) converts Big ET-1 into ET-1 
(1-31)  
 To verify if CMA1 has a role in the degradation of ET-1 or ET-1 (1-31) 
 To determine the Kinetic constants of CMA1 towards a fluorogenic substrate, Big ET-1 
and Ang I 
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 To verify if the chymase extracted from the LUVA cells (human Mast cell line) converts 
the Big ET-1 into ET-1 (1-31) 
 To verify if CMA1 extracted from soluble fractions of healthy human aortas would 
generate ET-1 (1-31) from the precursor Big ET-1 
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ABSTRACT 
 
Important structural differences imply that human and mouse mast cell chymases may differ with 
respect to their enzymatic properties. We compared in this study the catalytic efficiencies of 
recombinant human chymase (rCMA1) and its functional murine homologue recombinant mouse 
mast cell protease-4 (rmMCP-4) toward a fluorogenic chymase substrate (Suc-Ala-Ala-Pro-Phe-
7-amino-4-methylcoumarin (AMC) and by their ability to convert Big-endothelin (ET)-1 into 
ET-1 (1–31) using a LC/MS/MS system. Activities toward a fluorogenic substrate (Suc-Leu-
Leu-Val-Tyr-AMC) and Big ET-1 were also measured in extracts from mouse peritoneal mast 
cells, LUVA human mast cell-like cells and human aortas. The specificity of these activities was 
assessed with the chymase inhibitor TY-51469 (2-[4-(5-fluoro-3- methylbenzo[b]thiophen-2-yl) 
sulfonamido-3-methanesulfonyl-phenyl]thiazole-4-carboxylic acid). For similar affinities, 
rmMCP-4 showed a higher activity toward the fluorogenic substrate and a higher ability to 
process Big ET-1 as compared to recombinant CMA1 (chymase activity (kcat/KM in µM
-1s-1): 
2.29 x 10-4 vs. 6.41 x 10-6; ET-1 (1–31) production: 2.19 x 10-3 vs. 6.57 x 10-5), and both of these 
activities of mouse and human chymase were sensitive to TY-51469. Furthermore, extracts from 
mouse peritoneal mast cells, LUVA cells and human aorta homogenates contained processing 
activities toward the fluorogenic chymase substrate as well as Big ET-1, all of which were 
sensitive to TY-51469. Finally, the pressor responses to Big ET-1 but not to ET-1 were 
significantly reduced in conscious and free moving mMCP-4 KO mice when compared to wild 
type congeners. Our results suggest that both mouse and human chymases have potent ET-1 (1–
31)-producing abilities, with the murine isoform being more efficient. 
 
Keywords: Chymase, Recombinant enzymes, Mass spectrometry, Radiotelemetry, In silico 
analysis 
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1. Introduction 
Chymases are serine proteases released by activated mast cells, involved in tissue repair and 
inflammatory processes such as wound-healing/fibrosis [1], cardiac remodelling and 
angiogenesis [2,3]. In humans and rodents, two types of mast cells have been identified. Human 
mast cells positive for both chymase and tryptase (MCTC) are similar to murine connective 
tissue mast cells (CTMC) while those positive only for tryptase (MCT) resemble murine mucosal 
mast cells (MMC) [4,5]. To date, a single chymase, a-chymase or CMA1 [6] has been identified 
in humans, expressed in MCTC. In mice, mouse mast cell protease 4 (mMCP-4), predicted as a 
rodent b-chymase from its deduced amino acid sequence, shows angiotensin II (Ang II)- forming 
properties, CTMC localization and serglycin storage dependence [7] similar to those afforded by 
CMA1 [6]. Importantly, like the a-chymase CMA1 [8], mMCP-4 does not share the preferential 
b-chymase Tyr4-Ile5 cleaving activity on Ang-II that mMCP-1 and rat mast cell protease 1 
(rMCP-1, the mMCP-4 rat homolog) possess, making the mouse a more representative model 
than that of the rat to study human-like Ang-II formation [9]. mMCP-4 plays a protective role in 
a mouse model of cerebral trauma [10], yet is detrimental in bleomycin-induced lung 
inflammation and immune complex-induced glomerulonephritis [11,12]. 
The potent vasopressor peptide endothelin-1 (ET-1) on the other hand, is generated from a larger 
38 amino acid precursor Big-endothelin-1 (Big ET-1) via the hydrolytic activity of an 
endothelin-converting enzyme (ECE) [13]. Besides, other proteases are also involved in the 
overall production of mature ET-1. Among those, chymase derived from human purified 
pulmonary tissue cleaves the Tyr31–Gly32 bond of Big ET-1 (1–38) to yield ET- 1 (1–31) [14]. 
Our group later reported that ET-1 (1–31) requires a further neutral endopeptidase (neprilysin, 
NEP)-dependent hydrolysis of the Trp21–Val22 bond to produce mature ET-1 in vivo [15]. 
Whether mMCP-4 is also involved in the in vivo synthesis of endothelins remained unexplored 
until we recently reported that this particular chymase isoform converts Big ET-1 to ET-1 (1–31) 
and subsequently to ET-1 in a study using anesthetised mMCP-4-/- mice [16]. 
Human chymase generated by a recombinant approach produces chymostatin-sensitive Ang II 
from Ang I, with a KM of 59 µM [17]. Chymostatin however, a general chymotrypsin-like 
protease inhibitor, is much less specific than newer generation chymase inhibitors such as TY-
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51469 [18]. In addition, the comparative capacities of recombinant mMCP-4 and CMA1 to 
generate ET-1 (1–31) have not been assessed. 
Based on our previous reports on the chymase-dependent conversion of the precursor Big ET-1 
to ET-1 (1–31) in the anesthetised mouse model in vivo [16,19], we hypothesized that 
recombinant or mast cell-extracted mMCP-4 as well as CMA1, would generate the 31-amino 
acid intermediate in a TY 51469- sensitive fashion.  
The first principal aim of this study was therefore to compare, by using recombinant mMCP-4 
and its human counterpart CMA1, the capacity of murine and human chymases to generate ET-1 
(1– 31). A second aim was to assess the ET-1 (1–31)-producing capacities of chymases derived 
from mouse (peritoneal mast cells) and human mast cells (LUVA cells, [20]) as well as the role 
of chymase in the production of ET-1 (1–31) by human aortic biopsies. 
 Our data show that the murine mMCP-4 and the human CMA1 generate ET-1 (1–31) from the 
precursor Big ET-1 via recombinant enzymes as well as in cellular or tissue extracts of mouse 
and human origin. 
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2. Materials and methods 
 
 2.1. Drugs and chemicals  
Phosphate buffered saline (PBS) pH 7.4, ammonium hydroxide, bovine serum albumin (BSA), 2-
(N-morpholino)ethanesulfonic acid (MES), pluronic F-68, formic acid (FA), trifluoroacetic acid 
(TFA), and N-ethylmaleimide (NEM) were obtained from Sigma-Aldrich (Oak- ville, ON, 
Canada). The StemPro-34 SFM culture medium was purchased from Invitrogen (Carlsbad, CA, 
USA). The RPMI-1640 and I-Max (IPL-41) culture media, fetal bovine serum (FBS) and the 
antibiotics hygromycin B and penicillin were obtained from Wisent (Montreal, QC, Canada). 
Dithiotreitol (DTT), dimethyl sulfoxide (DMSO) and HPLC-grade acetonitrile (ACN) were 
obtained from Fisher Scientific (Ottawa, ON, Canada). Murine active cathepsin C and 
recombinant CMA1 were obtained from R&D Systems (Minneapolis, MN, USA). Heparin was 
purchased from LEO Pharma A/S, (Ballerup, Denmark). Triton X-100 was obtained from ICN 
Biochemical (Aurora, OH, USA). Suc-Ala-Ala-Pro-Phe-7-amino-4-methylcoumarin (AMC), 
Suc-Leu-Leu-Val-Tyr-AMC and ET-1 (1–31) were obtained from Peptide Institute (Osaka, 
Japan), Big ET-1, Ang-I, Ang-II and Pro11- DAla12-Ang-I were obtained from American 
Peptide Company (Sunnyvale, CA, USA), ET-1 was obtained from Tocris Bioscience (Bristol, 
UK) and (13C6)Leu
6-ET-1 was obtained from Bachem (Bubenford, Switzerland). Suc-Ala-Ala-
Pro-Phe-chloromethylketone (CMK) was obtained from MP Biomedicals (Santa Ana, CA, 
USA). Ketamine was obtained from Bioniche (Belleville, ON, Canada), xylazine from Bimeda 
(Cambridge, ON, Canada) and buprenorphine from Reckitt Benckiser Healthcare (Slough, 
United Kingdom). Finally, TY-51469 (2-[4-(5-fluoro-3-methylbenzo[b]thiophen-2-yl)sulfona- 
mido-3-methanesulfonylphenyl]-thiazole-4-carboxylic acid) was graciously provided by Toa 
Eiyo Ltd. (Osaka, Japan). 
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2.2. Expression, purification, activation and titration of recombinant mMCP-4 and CMA1  
2.2.1. Expression  
The vector pAc5.1 (Life Technologies, Burlington, ON, Canada) containing the recombinant 
DNA of pro-mMCP-4 or pro-CMA1, with poly-histidine and V5 tags, was co-transfected with 
the selection vector pCoHygro (Life Technologies) into S2 drosophila cells. The S2 cells were 
grown in I-Max culture medium IPL-41 complemented by 10% of fetal bovine serum (FBS) and 
hygromycin B (300 mg/ml). The cells were scaled up and finally suspended in serum-free culture 
medium containing 1% pluronic F-68 at a concentration of 2 x 106 cells/ml. 
2.2.2. Purification  
The crude extract sample containing the secretion of the drosophila cells was concentrated by 
ultrafiltration on an Ultracell Microcon 10 kDa filter (EMD Millipore, Billerica, MA, USA). 
This sample was then purified on a nickel affinity column by FPLC with an imidazole gradient 
(up to 250 mM) for isolation of poly-histidine tag positive samples. Those samples were then put 
on a Superdex200 26/60 size exclusion column (GE Life Sciences, CA, USA) and the V5-
positive fractions (determined by Western blot, data not shown) were pooled and frozen. 
2.2.3. Activation 
The recombinant enzymes were thawed and diluted to a concentration of 20 mg/ml in maturation 
buffer (50 mM MES, 0.1% BSA, pH 5.5,). Active murine cathepsin C was diluted to 0.481 ng/ml 
in cathepsin C buffer (50 mM MES, 50 mM NaCl, 5 mM DTT, pH 5.5). Activation was 
performed by adding equal volumes of recombinant chymase and cathepsin C, adding 50 µg/ml 
heparinand incubating 1 h at room temperature. Chymase activation was stopped with NEM (3 
mM) and diluted with assay buffer (20 mM Tris, 2 M KCl, 0.02% Triton X-100 (replaced with 
(0.1%) BSA for Ang- I assays), pH 9.0) to bring the recombinant chymase concentration to 2 
mg/ml, and 5 min was afforded to completely stop the cathepsin C-dependent reaction. 
2.2.4. Titration  
The activated recombinant enzymes (0.025 ng/ml rmMCP-4 or 0.25 ng/ml rCMA1) were 
incubated for 25 min at 37 ºC with multiple concentrations (1.12 x 10-6 to 1.12 x 10-9 M) of the 
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inhibitory substrate Suc-Ala-Ala-Pro-Phe-chloromethylketone (CMK). When cleaved, the CMK 
compound covalently binds to the active site of recombinant chymase and blocks it. After this 
incubation, the fluorogenic substrate Suc-Ala-Ala-Pro-Phe-AMC was added and the chymase-
like activity was analyzed as described in the main body of the article. The threshold of total 
inhibition of chymase activity was interpreted as the number of active sites in the recombinant 
chymases preparations and used as the molar concentration of enzymes for determination of their 
kinetics. 
 
2.3. Animals  
C57Bl/6J mice were purchased from Charles River (Montreal, QC, Canada) and housed in our 
facilities. Genitor mMCP-4 KO mice [2] were bred in our facilities. All animals were kept at 
constant room temperature (23ºC) and humidity (78%) under a controlled light/dark cycle (6:00 
AM–6:00 PM), with standard chow and tap water available ad libitum. Animal care and 
experiments were approved by the Ethics Committee on Animal Research of the University of 
Sherbrooke following the Canadian Council on Animal Care guidelines and the Guide for the 
Care and Use of Laboratory Animals of the United States National Institutes of Health. All 
experiments on mice were performed on newly sacrificed animals, except for telemetric 
hemodynamic recording performed on live animals. The mice underwent general anesthesia, by 
the intramuscular administration of ketamine/xylazine (87/13 mg/kg). Complete anesthesia was 
assumed when no withdrawing reflex was found during pressure on any paw of the mouse. 
Anesthetized mice were killed by cervical dislocation. 
 
2.4. Mast cell preparation  
Mouse peritoneal mast cells preparations were used, as they are readily available, fully mature 
connective tissue resident mast cells containing their full complement of granule proteases 
without being primed with cytokines [21]. 5 ml of isolation buffer (phosphate buffer solution 
containing 1 mg/ml of BSA and 37.5 U/ml heparin, pH 7.4) was introduced into the peritoneal 
cavity of mice after peritoneal skin removal, then collected after 1 min of peritoneal massage and 
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centrifuged (200 x g, 5 min). In another series of experiments, mast cell-like LUVA cells were 
maintained in a StemPro1-34 SFM solution at a cell density of 5 x 105cells/ml, in the absence of 
additional growth factors. The suspension was divided into 2 equal volumes of 30 ml and 
centrifuged (200 x g, 5 min). Treatment of LUVA and mouse mast cell pellets was similar 
thereafter. The supernatant was discarded and the mast cell rich pellet was suspended in RPMI-
1640 medium (enriched with penicillin (100 U/ml), 2 mM L-glutamine and BSA (1 mg/ml)) and 
incubated for 1 h at 37 ºC. The suspension was centrifuged for 5 min at 200 x g, the supernatant 
was discarded and the pellet was suspended in isolation buffer. The cells were counted according 
to the Moore and James method [22] and adjusted to 2 x 105mast cells/ml in PBS pH 8. The cells 
were lysed through sonication and then centrifuged at 200 x g for 5 min. The resulting pellet was 
washed thrice in 0.1 M PBS pH 8.0 by further centrifugation cycles. 
 
2.5. Human aortas preparation  
The human aortas were collected from middle-aged brain-deceased individuals with no 
histological signs of atherosclerosis. The tissues were weighed and grinded in PBS on ice by a 
tissue homogenizer (Polytron, ultra-turax T8, IKA, Wilmington, NC, USA) for 30 s. 
Centrifugation for 20 min at 25,000 x g at 4 ºC took place then the soluble fractions 
corresponding to the supernatant were collected and frozen at -80 ºC. 
 
2.6. Specific chymase activity in vitro  
Activated rmMCP-4 (0.025 ng/ml), activated rCMA-1 (0.25 ng/ml) or mast cell extracts (from 4 
x 105 peritoneal mouse mast cells or LUVA cells) were incubated in a 96 well plate. Increasing 
concentrations of the non-fluorescent substrates Suc-Ala-Ala-Pro- Phe-7-amino-4-
methylcoumarin (AMC) (for recombinant enzymes) or Suc-Leu-Leu-Val-Tyr-AMC (for mast 
cell and tissue extracts) were added and the fluorescence AMC-forming activity, as chymase 
activity, was then measured with a fluorescence spectrophotometer (λex: 370 nm; λem: 460 nm) 
for 20 min (Molecular Devices, Sunnyvale, CA). Another series of experiments was performed 
at 10 µM of fluorogenic substrate with pretreatment of the diluted samples with the specific 
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chymase inhibitor TY-51469 (10–50 µM). To determine enzyme kinetics, the recombinant 
enzyme active sites were titrated with the inhibitor substrate Suc-Ala-Ala-Pro-Phe-CMK. 
 
2.7. In vitro conversion of Big ET-1 to ET-1 (1–31) and Ang-I to Ang-II  
2.7.1. Recombinant enzymes  
Big ET-1 and Ang-I dilutions were prepared in 0.1 M PBS pH 8.0. The recombinant enzymes 
(28.57 ng/ml activated rmMCP-4 or 1428 ng/ml activated rCMA1) were incubated at 37 ºC with 
Big ET-1 (0.15, 0.75, 1.5, 4.5, 7.5, 15 and 26 µM) or Ang-I (1.5625, 3.125, 6.25, 12.5, 25, 50 
and 100 µM) for 20 min, after which the reactions were stopped with an equal volume of 
water:acetonitrile:dimethylsulfoxide:formic acid (H2O:ACN:DMSO:FA) mix (73:20:6:1) 
containing (13C6)Leu
6-ET-1 (100 µg/ml) or a H2O:ACN:FA mix (76:20:4) containing Pro11-
DAla12-Ang-I (176 ng/ml) (peptides as internal standards). In another series of experiments, 
16.7 µM of Big ET-1 was incubated in the presence of TY-51469 (10 µM) and the reaction was 
stopped as described above. Samples were diluted 1:10 with the same stop solution without the 
internal standard before LC–MS/MS analysis. Kinetics parameters were calculated using Prism 
Software (GraphPad, La Jolla, CA, USA). 
 2.7.2. Mast cell and aortic extracts 
 In another series of experiments, the soluble fractions of 9 x 105 WT peritoneal mouse mast 
cells, 4 x 106 LUVA cells or the soluble fraction of the human aortas (adjusted to 2.2 mg/ml of 
protein) were pretreated with vehicle or TY-51469 (10 µM) and then incubated with Big ET-1 at 
37 ºC at concentrations of 5, 5 and 13 µM, respectively, for 20 min. The reactions were stopped 
in with the stop solution described above containing (13C6) Leu
6-ET-1 (50 ng/ml) and 
subsequently processed by solid phase extraction (SPE) before LC-MC/MS analysis, albeit the 
stop solution for the human aorta assay was ACN:DMSO:FA (88:6:6). 
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2.8. LC–MS/MS quantification of Big ET-1, ET-1 (1–31) and ET-1  
2.8.1. Sample preparation  
For in vitro conversion by recombinant enzymes, samples were analyzed directly. For analysis of 
samples from masts cells or human aortic tissue, SPE was performed consisting of a polymeric 
mixed mode strong cation exchange 1 ml cartridge containing 30 mg of sorbent (Phenomenex, 
Strata-X-C, Torrance, CA, USA).Briefly samples were pre-treated with 2% FA and loaded on 
the SPE column, samples were next washed once with 60% methanol containing 2% FA and 
eluted with 2 x 700 µl of 75% ACN containing 10% ammonium hydroxide. 
2.8.2. System description 
Analysis was performed by LC–MS/MS on TripleTOF 5600 mass spectrometer (ABSciex, 
Foster City, CA, USA) equipped with DuoSpray source. Samples were introduced to the 
electrospray ionization (ESI) source in a 50 µm ESI probe using a microLC200 system equipped 
with a 50 mm x 500 µm HALO C18 2.7 µm column. 
2.8.3. System conditions  
Chromatography was performed with a gradient of water containing 0.2 % formic acid and 3% 
DMSO (A) and ACN containing 0.2% formic acid 3% DMSO (B) (without DMSO for Ang-II 
determination). For endothelin peptides analysis, column temperature was set at 50 ºC. A 4 min 
gradient was run at 40 µl/min. It consisted of the following steps: hold at 10% B from 0 to 0.5 
min, 10% B to 75% from 0.5 min to 2.7 min, hold at 100% B from 2.9 to 3.4 min and 
equilibration from 3.5 to 4 min at 10% B. Source parameters where the following: curtain gaz 
was set at 28, gaz 1 was set at 17, gaz 2 was set at 28, ion source voltage was set at 5500 and ESI 
probe temperature was set at 375. For Ang-II analysis, a 2.5 min gradient was run at 40 µl/min. It 
consisted of the following steps: hold at 15% from 0 to 0.4 min, 15% B to 100% from 0.4 min to 
1.4 min, hold at 100% B from 1.4 to 2.9 min and equilibration from 2 to 2.5 min at 15% B. 
Source parameters where the following: curtain gaz was set at 27, gaz 1 was set at 25, gaz 2 was 
set at 20, ion source voltage was set at 4900 and ESI probe temperature was set at 400. 
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2.8.4. Analysis  
Compounds were monitored using optimized collision energy parameter in product ion mode at 
unit resolution with a mass range from 100 to 2000 m/z in high sensitivity MS/MS scan. Data 
integration and analysis was performed using MultiQuant software V2.0 with the signal finder 
algorithm (ABSciex) by selecting the appropriate product ion transition with a mass range of 
0.05 Da subsequently analyzed. 
 
2.9. Effect of recombinant CMA1 or mMCP-4 on ET-1 (1–31) in vitro  
The activated recombinant enzymes were incubated with ET-1 (1–31) (3.2 µM) for 20 min at 37 
ºC, after which samples were filtered through a 30 K Amicon centrifugal filter unit (Millipore 
Corporation, Billireca, MA, USA) (14,000 x g, 20 min) for high performance liquid 
chromatography (HPLC) analysis. Filtrates were collected and purified by reversed phase HPLC 
(1100 series) with a Zorbax DSC-18 analytical column (Agilent Technologies, Santa Clara, CA). 
The flow was 1 ml/min, water was used as solvent, acetonitrile as eluent, 0.1% trifluoroacetic 
acid as buffer and the acetonitrile fraction going from 28% to 40% in 35 min. Quantification was 
assessed with absorbance at a wavelength of 214 nm using area under the curve measurements 
(in arbitrary units). 
 
2.10. Telemetric hemodynamic recording of the pressor activity of Big ET-1 in conscious mice 
2.10.1. Probe implantation  
Telemetry probe implantation was achieved in accordance to Carlson and Wyss [23] and Butz 
and Davisson [24]. Briefly, ketamine/xylazine-anesthetised WT and mMCP-4 KO mice were 
implanted with a catheter-tipped transmitter (TA11PA-C10; Data Sciences International, St. 
Paul, MN, USA) into the aortic arch via the left common carotid artery. The transmitter was 
placed subcutaneously along the right flank of the animal. A buprenorphine protocol of 0.1 
mg/kg every 8 h for 24 h post-operation was conducted to control surgical pain. The mice had a 
10-day recovery period before recording of hemodynamic data. 
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2.10.2. Hemodynamic recording  
The mice were trained to the contention chamber with saline injections through the caudal vein 
to minimize stress. After two training sessions, the mice received Big ET-1, Ang-I (both at 1 
pmol/kg), ET-1 or Ang-II (both at 0.1 pmol/kg) intra-caudally (200 µl injection) and 
subsequently released in their cage. Hemodynamic recording in the freely moving mouse was 
performed every 30 s, each data point representing a 10 s average, for 1 h via Acquisition 
Dataquest 4.33 (Data Sciences International). 
 
2.11. In silico analysis  
The X-ray structure of the complex of human chymase (CMA1) and a substrate analog (Protein 
Data Bank code; 1PJP) [25] was used as the template for homology modeling of mouse chymase 
(mMCP-4), and the mouse molecular model was optimized by energy minimization using 
Amber12 force fields [26]. Big ET-1 (28-35) binding structure on the active site of each chymase 
model was constructed referencing the substrate analog in 1PJP. Each complex model was 
optimized by 100 ps molecular dynamics simulation using the same force fields and a periodic 
cube of water molecules as solvent, and the most stable structure during the latest 25 ps iterations 
was finally optimized by energy minimization. All of the molecular operations, including 
molecular dynamics simulation, were performed using a package for molecular structural 
analyses, MOE 2012 (Molecular Operating Environment, Chemical Computing Group Inc., 
Montréal, QC, CA). 
 
2.12. Data analysis  
All data are presented as the means ± the standard error of the means (SEM) unless otherwise 
stated. Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software Inc, La 
Jolla, CA, USA). Statistical significance was assessed using Student’s t-test and assumed when 
the p value was lower than 0.05. 
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3. Results  
 
3.1. Enzyme kinetics of recombinant mMCP-4 and CMA1  
In this first series of experiments, the comparative kinetics of recombinant mMCP-4 and CMA1 
were established via the hydrolysis of the fluorogenic substrate Suc-Ala-Ala-Pro-Phe-AMC (Fig. 
1A and C) or production of ET-1 (1–31) from Big ET-1 quantified by LC–MS/MS (Fig. 2A and 
C). All measured parameters are summarized in Table 1 which also includes parameters for Ang- 
I to Ang-II conversion. 
Albeit both enzymes possess equivalent affinities against both substrates, mMCP-4 shows higher 
efficacy (in terms of kcat/KM) than CMA1 to hydrolyse the fluorogenic peptide or the precursor of 
ET-1 (1–31) (Table 1). In addition, TY-51469 (10 µM) abolished the activity of both enzymes 
(Figs. 1B, D and 2B, D) (** p < 0.01, n = 6). Lower concentrations of TY-51469 (0.5 and 1 µM) 
partially inhibited the hydrolysis of the fluorogenic peptide (results not shown). In addition, 
neither recombinant mMCP-4 nor CMA1 degraded ET-1 (1–31) (Fig. 2E). As a last series of 
controls, the kinetics of both enzymes were experimentally determined against the hydrolysis of 
angiotensin I to angiotensin II with similar Vmax and KM to those observed with both enzymes 
against the production of ET-1 (1–31) (Table 1). Michaelis–Menten curves for both recombinant 
enzymes against Ang-I are shown in supplementary figure S1. The activity of in-house produced 
rCMA1 was similar to the activity of commercially available rCMA1 on Ang-II production from 
Ang-I (data not shown). 
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Figure 1: Fluorescence production by recombinant enzymes. The fluorescence-production rate of 
recombinant mMCP-4 (A; n = 7) and CMA1 (C; n = 6) was measured at different fluorogenic 
substrate concentrations of 5, 10, 15, 25, 50, 100 or 250 µM. Data points are expressed as means 
± SEM. Time-course of the fluorescence production of typical experiments with mMCP-4 (B) 
and CMA1 (D) with 10 µM of Suc-Ala-Ala-Pro-Phe-AMC which was inhibited in the presence 
of TY-51469 (10 µM). 
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Figure 2: Big ET-1 is converted to ET-1 (1–31) by recombinant enzymes. The rate of 
reactions at different concentrations of Big ET-1 of 0.15, 0.75, 1.5, 4.5, 7.5, 15 or 26 µM for 
recombinant mMCP-4 (A; n = 6) and recombinant CMA1 (C; n = 7) is shown. (B and D) 
Quantification of the in vitro conversion of 16.7 µM of Big ET-1 to ET-1 (1–31) by mMCP- 4 
(B) and CMA-1 (D) in the absence (n = 3) or presence (n = 6) of TY-51469 (10 µM) shows that 
chymase inhibition abolishes the conversion of Big ET-1 to ET-1 (1–31). (E) Reverse-phase 
HPLC quantification of ET-1 (1–31) (3.2 µM) degradation by mMCP-4 and CMA1 shows no 
activity of the recombinant enzymes on ET-1 (1–31) (n = 4). Data points are expressed as means 
± SEM. 
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Table 1 Enzyme kinetics of rmMCP-4 and rCMA 1 against a fluorogenic substrate, Big 
ET-1 (1–38) or Angiotensin I. 
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3.2. TY-51469-sensitive chymase activity and conversion of Big ET-1 to ET-1 (1–31) in mouse 
and human-like mast cells  
Fig. 3A shows that WT mouse peritoneal mast cell extracts exhibit a TY-51469-sensitive 
chymase-like activity that is abolished in extracts from mMCP-4-/- mast cells. Soluble extracts 
from LUVA cells also exhibited chymase-like activity, with higher concentrations of TY-51469 
required to significantly inhibit the production of ET-1 (1–31) (Fig. 3C). Conversion of Big ET-1 
to ET-1 (1–31) occurred in whole cell extracts of peritoneal mast cells derived from WT, but not 
in those derived from mMCP-4-/- mice. In addition, TY-51469 (10 µM) reduced by more than 
80% the production of ET-1 (1–31) in fractions derived from wild type mice (** p < 0.01, n = 7, 
Fig. 3B). Fig. 3D shows the conversion of Big ET-1 to ET-1 (1–31) in whole cell extracts of 
LUVA cells, which was inhibited by 50% by the specific chymase inhibitor. 
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Figure 3: Chymase activity by mast cell extracts. The fluorescence production using Suc-Leu-
Leu-Val-Tyr-AMC (10 µM) by mouse peritoneal mast cell extracts from WT and mMCP-4-/- 
mice (A) and LUVA cells (C) was inhibited by TY-51469 (10 µM). Big ET-1 (15 µM) was 
converted in vitro to ET-1 (1–31) by homogenates of WT or mMCP-4-/-peritoneal mast cells (B) 
and human LUVA cells (D), and this activity was inhibited by TY-51469 (10 µM) (n = 8). Data 
points are expressed as means ± SEM. 
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3.3. Hemodynamics responses to Big ET-1 and Ang-I in conscious WT or mMCP-4_/_ mice 
In Fig. 4, panels A–C show the variation in the mean (A), systolic (B) and diastolic (C) arterial 
pressures, respectively, following caudal vein administration of Big ET-1 (1 pmol/kg). Big ET-1 
increased mean arterial pressure by 56.6 ± 7.7 mmHg in WT mice (n = 11) whereas the same 
response was reduced in mMCP-4-/-(34.3 ± 4.2, n = 9, *: p < 0.05) by 43%, similarly to systolic 
and diastolic blood pressure responses in both mouse strains. 
In contrast, intravenous (i.v.) administration of ET-1 prompted similar increases of mean arterial 
blood pressure in WT or mMCP-4-/-mice (WT: 42.70 ± 1.89; mMCP-4-/-: 43.92 ± 6.39 mmHg, n 
= 5). 
Finally Ang-I (1 pmol/kg, i.v.) (WT: 38.34 ± 1.91;mMCP-4-/-: 44.07 ± 3.87 mmHg) or Ang-II 
(0.1 pmol/kg) (WT: 37.00 ± 3.61; mMCP-4-/-: 42.09 ± 3.33 mmHg) also induced similar 
increases ofMAP in WT and mMCP-4-/-mice (n = 5 for each series of experiments). 
Basal mean arterial pressure in all telemetry-instrumented mice was averaged at 107.56 ± 5.61 
(WT) or 110.70 ±4.17 mmHg (mMCP-4-/-) and basal heart rate at 571.65 ± 31.55 bpm (WT) or 
615.46 ± 42.00 bpm (mMCP-4-/-). 
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Figure 4: Hemodynamic response to Big ET-1 in instrumented conscious WT or mMCP-4-/- 
mice. All mice were instrumented with a catheter in the aortic sinus connected with a wireless 
pressure transducer. Panels A, B and C show the variation in the mean (A), systolic (B) and 
diastolic (C) arterial pressure measurements, respectively, following caudal vein Big ET-1 
administration (1 pmol/kg). Big ET-1 increased mean arterial pressure by 56.6 ± 7.7 mmHg in 
WT mice (n = 11), and this response was diminished in mMCP-4-/- (34.3 ± 4.2, n = 9, *: p < 
0.05) by 43%, similarly to systolic and diastolic blood pressures. Big ET-1, on the other hand, 
did not induce changes in the heart rate (D) in both WT and mMCP-4 KO mice (measures taken 
at the time of maximal variation of mean arterial blood pressure following saline or Big ET-1 
administration). Each data point is expressed as mean ± SEM. 
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3.4. Human aortic homogenates generate ET-1 (1–31) in a TY-51469- sensitive fashion  
Fig. 5 shows the conversion of Big ET-1 to ET-1 (1–31) in soluble fractions of human aorta. 
Addition of TY-51469 at a concentration of 10 µM resulted in the suppression of ET-1 (1–31) 
production in aortic extracts. Fig. 5A and B shows representatives spectra of the peptide products 
detected by LC–MS after incubation of Big ET-1 (13 µM) with aortic extracts in absence (A) or 
presence of the chymase inhibitor TY-51469 (B). Two major ionization species are detected for 
Big ET-1 and ET-1 (1–31) (z = 5 and z = 4 for Big ET-1, z = 4 and z = 3 for ET-1 (1–31). Co-
treatment with the chymase inhibitor TY-51469 abolished the ET-1 (1–31) signal (Fig. 5B). Fig. 
5B insert illustrates the quantification of ET-1 (1–31) production over 6 experiments in human 
aortic homogenates, inhibited by over 90% by TY-51469. 
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Figure 5: Representative LC/MS/MS mass spectra of the conversion of Big ET-1 to ET-1 
(1–31) by human aortic homogenates. Incubation of homogenates of human aortas with Big 
ET-1 (13 µM) (#) resulted in the production of ET-1 (1–31) (y) specific peaks, in the absence 
(A) but not in the presence of TY-51469 (10 µM; B). For both peptides, major both ionization 
species are labeled (from left to right, z = 5 and z = 4 for Big ET-1, z = 4 and z = 3 for ET-1 (1–
31)). In the insert is the quantification of the in vitro conversion of Big ET-1 (13 µM) to ET-1 
(1–31) in homogenates from human aortas (n = 6). Data points are expressed as means ± SEM. 
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3.5. In silico analysis  
As shown in Fig. 6A, the Tyr31 (P1) side-chain of Big ET-1 (28-35) was able to fit the S1 hole of 
mMCP-4, and the Leu33 (P20) side-chain of Big ET-1 interacted with the hydrophobic moiety of 
Lys192 of mMCP-4. By these interactions, the carboxyl group of Tyr31 could be fixed by 
hydrogen bonds to both Gly193 and Ser195 amine groups in the ‘anion hole’ of mMCP4. However 
the part of P30 and P40 (Big ET-1 Gly34 and Ser35) being highly flexible, a hydrogen bond was 
formed between Ser35 (of Big ET-1) and Thr41 (on mMCP-4) in this structure. On the other hand, 
Leu33 of Big ET-1 (28-35) was stabilized with Phe41 in CMA1 by hydrophobic interaction 
between side chains and hydrogen bonds between main chains (B). Compared with the above 
model of mMCP-4, these tight interactions of Leu33 (of Big ET-1) with Ph41 in CMA1 appear to 
restrict the access of the CMA1 Lys192 moiety to the octapeptide,and the carboxyl group of Tyr31 
of Big ET-1 (28-35) can then only interact with the amine of Gly193 in the ‘anion hole’ of CMA1. 
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Figure 6: Predicted molecular structures of the complex of Big ET-1 with mMCP-4 or 
CMA1. Predicted molecular structures around the active sites of mMCP-4 and CMA1 
interacting with Big ET-1 (28-35), CH3CO-Val-Val-Pro-Tyr-Gly-Leu-Gly-Ser-NHCH3, are 
shown in (A) and (B), respectively. Each chymase and its active center residues are described by 
a white and light-green stick model, and the Big ET-1 fragment is colored in light blue. Oxygen, 
nitrogen and sulfur atoms are colored in red, blue and yellow, and hydrogen atoms were omitted. 
Hydrogen bond distance between chymases and Big ET-1 is colored in green. The molecular 
surface of atoms related to the interaction of ‘anion hole’ is shown transparently. In the active 
site of CMA1 (B), the hydrogen bond between Ser195 –NH and Big ET-1– Tyr31(P1) >C5O was 
lost (interatomic distance = 4.79 A˚). (For interpretation of the references to color in this figure 
legend, the reader is referred to the web version of this article.) 
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4. Discussion  
 
Our main results support the concept that both recombinant murine and human chymases are 
able to generate ET-1 (1–31) from its precursor Big ET-1 and that a specific chymase inhibitor, 
TY-51469, abolishes this process. The kinetics of either recombinant enzymes to produce ET-1 
(1–31) or Ang-II from Ang-I, in terms of KM and Vmax are similar. In addition, the ET-1 (1–31) 
producing capacities of recombinant mMCP-4 and CMA1 are extended to chymase-like activity 
derived from mouse or humanmast cells as well as from human blood vessels. The results shown 
in the present study with recombinant mMCP-4 support our previous report identifying mMCP-4 
as the sole murine chymase isoform involved in the genesis of exogenous and endogenous ET- 1 
in vivo [16]. Our results for the conversion of Ang-I to Ang-II by rCMA1 and rmMCP-4 in vitro 
are also in accord with the literature [5,9]. 
In our experimental conditions, mMCP-4 was found to be more efficient than CMA1 to generate 
ET-1 (1–31) from its precursor, based on the Kcat/KM of each enzyme. The in silico analyses 
presented in this study suggest that the peptide link between Tyr31(P1) and Gly32(P10) of Big 
ET-1 would be closer to the active center of mMCP-4 than that of CMA1, thus explaining the 
higherefficiency of the murine chymase when compared to its human counterpart. Worthy of 
mention, in silico analysis were performed with the octapeptide chain susceptible to chymase 
hydrolytic activity rather than the entire 38 amino acid sequence of Big ET-1. 
Interactions of either mMCP-4 or CMA1 binding and/or catalytic sites with N- and C-terminal 
chains and to the two disulfide bridges of the 38 amino acid precursor are unaccounted for in the 
present computer assisted modeling. 
Our group has previously shown that soluble extracts derived from mouse organs such as the 
heart, lungs, kidney and aorta hydrolyze the fluorogenic peptide Suc-Leu-Leu-Val-Tyr-7-amino- 
4-methylcoumarin (AMC), a chymotryptic activity which is only partly inhibited by TY-51469 
or in tissues derived from mMCP-4-/- mice, thus suggesting that other proteases are involved in 
the process [16]. In contrast, we show in the present study that the TY- 51469-sensitive 
hydrolysis of a fluorogenic peptide by extracts from mouse mast cells is totally dependent on the 
presence of mMCP-4. Furthermore, the extracts derived from mouse mast cells show the 
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exclusive contribution of mMCP-4 in the processing of Big ET-1 to ET-1 (1–31). Our data 
further suggest that mMCP-4 isthe predominant isoform involved in the conversion of Big ET-1 
to ET-1 (1–31) in these cells since no more than 20% of the latter peptide were found in soluble 
extracts derived from mMCP-4-/- mice or from WT extracts pre-treated with TY-51469. Whether 
the mMCP-4-dependent hydrolysis of Big ET-1 reported in our study in peritoneal mast cells can 
be reproduced in bone marrow derived mastocytes, remains to be investigated. 
We previously reported lower endogenous ET-1 levels in the lungs of mMCP-4-/-mice [16], in 
concordance with results from ECE-1-/-ECE-2-/- mouse embryos which show only a 45% 
reduction in whole body ET-1 levels [28]. Furthermore, anesthetized mMCP-4-/-mice, when 
compared to WT mice, produced half the plasma ET-1 and ET-1 (1–31) levels as well as pressor 
responses, when challenged with intravenous Big ET-1 [16]. In concordance with those results, 
we show here for the first time in freely moving, conscious mice that Big ET-1 is less potent as a 
vasoconstrictor in mMCP-4-/- mice than in their WT congeners whereas in contrast, both murine 
strains respond equally to Ang-I and Ang-II. This suggests that albeit purified or recombinant 
chymases (of mouse or human origins) can convert Ang-I to Ang-II in vitro as previously 
reported [8,9,27], it is not as biologically significant as for Big ET-1 in the murine systemic 
circulation given the abundance of angiotensin converting enzyme in vivo. This study also 
addressed the capacity of human tissues to generate ET- 1 (1–31) in a chymase inhibitor-
sensitive fashion. The LUVA cells used in the present study originate from the first human mast 
cell line derived from an individual without a clonal mast cell disorder, as indicated by normal 
serum tryptase levels in the patient and on the presence of metachromatic granules in those 
mastocytes [20,29]. This is also the first human mast cell line expressing a functional chymase 
[29]. Similarly to the recombinant enzymes and the extracts derived from mouse peritoneal mast 
cells, a TY- 51469-sensitive and chymase-dependent conversion of Big ET-1 to ET-1 (1–31) was 
observed in LUVA cells albeit less efficiently than with pure enzymes or mouse cells. The latter 
characteristic of LUVA cells may be explained by the heterogeneous expression of chymase in 
this particular cell line as reported initially by Laidlaw and colleagues [29]. Interestingly, in stark 
contrast to mouse peritoneal mast cell granular extracts, significant quantities of fluorescence 
and ET-1 (1–31) produced from Big ET-1 in LUVA granular extracts were TY-51469 
insensitive, suggesting that yet to be identified enzymes other than chymase, perhaps such as 
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cathepsin G [30], have chymotrypsin-like activity and generate the 31 amino acid intermediate in 
this particular cell model. 
Finally, similarly to pulmonary tissue investigated previously [14,16], soluble extracts of human 
aortic biopsies were found to generate ET-1 (1–31) with no further conversion to ET-1 in a TY- 
51469-sensitive fashion. In contrast to experiments with LUVA cells, conversion of Big ET-1 to 
ET-1 (1–31) by human aortic homogenates was fully inhibited by TY-51469 at 10 µM, in 
agreement with our results from the murine system and when using human recombinant CMA1. 
Thus, the present study suggests for the first time that the production of ET-1 (1–31) requires a 
chymase-like activity in human blood vessels. Interestingly, Mawatari and colleagues [31] 
reported ET-1 (1–31) reactivity in all vascular layers in the hamster aortic arch, which is 
increased in the intimal lesions of hypercholesterolemic animals. However, chymase-dependent 
generation of ET-1 (1–31) remains to be confirmed as a relevant factor in human atherosclerosis. 
The present study did not address the ECE/chymase conversion ratio in murine and human tissue 
extracts. However, it is of interest to note that no ECE-dependent synthesis of ET-1 from 
exogenous Big ET-1 was detected by the LC–MS/MS approach. This could perhaps be due to the 
experimental conditions imposed throughout the present study, such as the removal of non-
soluble proteins. It is possible that the ECE-dependent production of ET-1 would have been 
measurable in intact tissues or organs, particularly in conditions where the vascular endothelium 
would have been maintained intact. We suggest that, similarly to the angiotensin converting 
enzyme/chymase paradigm in the production of angiotensin-II from angiotensin-I [32], the ECE 
plays an important role in the production of the circulating levels of ET-1 whereas chymase-like 
activity may be predominantly involved in perivascular and tissue-derived genesis of the latter 
vasoactive peptide. 
Taken together, the present study supports an important role for both murine and human 
chymase in the production of the intermediate ET-1 (1–31). Our results further suggest that the 
use of chymase inhibitors in clinical settings may be proven useful not only for inhibiting 
intramural angiotensin II but also by reducing tissue levels of endothelin-1, particularly in 
cardiovascular diseases of fibrotic origin in which infiltration of activated mast cells is well 
documented [1]. 
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Discussion  
The main conclusion of this work is that the human chymase CMA1 and its murine homolog 
mMCP-4 be it recombinant, extracted from mast cells or from the soluble fractions of the human 
aorta (in the case of CMA1 only) convert Big ET-1 into ET-1 (1-31) in a TY-51469 sensitive 
fashion in vitro. Moreover, the importance of the chymase pathway in the conversion of Big ET-
1 into ET-1 and its paramount role in hypertensive responses was confirmed in conscious mice in 
vivo. 
The initiation of our experiments was based on the fact that our group has demonstrated that the 
mMCP-4 has the capacity to cleave Big ET-1 into ET-1 (1-31) in vivo and in vitro (Houde et al., 
2013). In the mouse model, there are 4 isoforms of chymase, 1 α-chymase and 3 β-chymases 
whereas in humans there is only 1 α-chymase identified. Several studies have been performed to 
identify the murine homolog of the human chymase and its implication in the endothelin system. 
The murine mMCP-5 is the only α-chymase; however it does not have chymase properties but 
elastase ones (Kunori et al., 2002) which indicate that it is less likely to be involved in the 
genesis of the endothelin system. Of the 3 β-chymases, the mMCP-4 was demonstrated to be the 
homolog of human chymase since both enzymes are activated by heparin in a similar way and 
they are both able to generate Ang II from its precursor Ang I (Caughey et al., 2000; 
Tchougounova et al., 2003; Wu et al., 2005). 
Very few studies have attempted to characterize recombinant chymases (murine or human) vis-à-
vis the Big ET-1. The literature shows a chymostatin, a non-specific chymase inhibitor, 
dependent characterization of CMA1 in regards to generation of Ang II from Ang I (Murakami 
et al., 1995) and different characteristics (regarding enzyme kinetics) of mMCP-4 and CMA1 
with Ang I or Big ET-1 as substrates (Takai et al., 1997, 1999; Caughey et al., 2000; Kunori et 
al., 2005). Regarding mMCP-4, Kinetic constants were established for the tissue purified enzyme 
using Ang I as a substrate (Caughey et al., 2000; Kunori et al., 2005). However no study to date 
was found to have used Big ET-1 as a substrate to characterize the enzyme; moreover, 
recombinant mMCP-4 was never tested in the literature. On the other hand, more studies 
involving CMA1 were published. In 1997, the group of Takai has characterized CMA1 purified 
from gastroepiploic arteries of donors suffering either from gastric cancer or gastric ulcers; 
although the donors did not have hypertension or diabetes mellitus, they were not healthy donors. 
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In this study, the authors have used Ang I as a substrate. In 1999, the group of Takao has used 
purified vascular CMA1 and has characterized the enzyme using Ang I and Big ET-1 (Takao et 
al., 1999). In that study the effect of deglycosylation of Asn-89 of CMA1 on its affinity and 
efficiency in processing Ang I and Big ET-1 were tested. Takao and colleagues have established 
in 1999 a KM and a Kcat/KM for the purified CMA1. It is important to note that in the two above 
mentioned studies, a purified enzyme was experimented. This purified enzyme was identified as 
chymase since it was inhibited by SBTI, PMSF and chymostatin but not inhibited by EDTA, 
pepstatin and aprotinin. As previously mentioned in the introduction, chymostatin is not a 
specific chymase inhibitor and it has shown to inhibit elastase II, an enzyme involved as well in 
the production of Ang II from its precursor Ang I (Becari et al., 2005). This drives us to the 
conclusion that the purified enzyme utilized in the studies might contain other enzymes or 
impurities able to cleave Ang I. This pushed us to use a more specific enzyme that will inhibit 
chymase solely. 
In 1999, the group of Takai has published another study comparing enzyme kinetics of the 
purified CMA1 to the recombinant CMA1. The authors have used Ang I and Big ET-1 as 
substrates. The authors have established a KM value for CMA1 (purified and recombinant), 
showing their affinities to Ang I and Big ET-1. In addition they have established a Kcat/KM value 
for both enzymes using Ang I as a substrate; however the Kcat/KM value for CMA1 with Big ET-
1 as a substrate was not published.  
To date, there is no study comparing the human and murine enzymes in the same paper, using 
the same experimental conditions. Furthermore, the efficiency of recombinant CMA1 in regards 
to cleaving Big ET-1 was not characterized in the literature, hence the important and innovative 
aspect of our study that compares CMA1 and mMCP-4 and establishes an affinity and efficiency 
of both enzymes. This comparison is valuable since mMCP-4 was shown to be the murine 
homolog of CMA1. Thus understanding its relative characteristics in vitro and in vivo can help 
with testing inhibitors (at different concentrations) in mice which can give an idea about the 
inhibitor’s concentrations needed in humans for an adequate response specially when developing 
new drugs targeting CMA1.  
In a first series of experiments, we have used a fluorogenic substrate that is cleaved by 
chymotypsin-like enzymes and verified the effect of TY-51469, a specific chymase inhibitor, on 
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CMA1 and mMCP-4 cleavage activity of the substrate. The inhibition of the fluorogenic activity 
was complete, confirming that our recombinant chymases (CMA1 and mMCP-4) are pure. This 
total inhibition was not noted in the work of Houde and colleagues in 2013, there was an 
important however partial inhibition of the murine chymase activity. The incomplete inhibition 
of the cleavage of the fluorogenic substrate was because our laboratory has used the soluble 
fractions of tissues of different organs which contain mMCP-4 among other proteases that have 
chymotrypsin-like activity and might have cleaved the fluorogenic substrate (Houde et al., 2013) 
whereas in the current study we have used recombinant enzymes. 
 The same activity of cleavage of the fluorogenic substrate observed with the soluble fractions of 
organs of WT mice pre-incubated with TY-51469, was seen in the soluble fractions of organs of 
mice mMCP-4 KO in the study of Houde and colleagues explaining that this remaining activity 
of cleavage is not due to chymase.  
However this partial inhibition was not noted in the generation of ET-1 (1-31) from Big ET-1 
incubated with soluble fractions of organs of WT mice, detected by HPLC; the inhibition was 
total. This suggests that the enzymes that have chymotrypsin-like activity and have the ability to 
cleave the fluorogenic substrate do not have any role in the cleavage of Big ET-1 into ET-1 (1-
31). Moreover, both recombinant chymase incubated with ET-1 (1-31) and/or ET-1 did not 
cleave these peptides.  
In another series of experiments, we have demonstrated that TY-51469 can inhibit the production 
of ET-1 (1-31) when pre-incubated with the recombinant enzymes mMCP-4 and CMA1; 
confirming once more that the recombinant enzymes are pure up to 99%. The concentrations of 
ET-1 (1-31) generated with mMCP-4 seemed to be more elevated than the ones generated by 
CMA1 indicating that mMCP-4 might be more efficient in cleaving Big ET-1. 
Furthermore, mMCP-4 extracted from murine peritoneal mast cells was able to cleave the 
fluorogenic substrate. An action totally inhibited by TY-51469 demonstrating that in the mast 
cells mMCP-4 are the only enzymes that have a chymotrypsin-like activity. 
The ability of mMCP-4 extracted from murine peritoneal mast cells to generate ET-1 (1-31) was 
also confirmed. The total inhibition of the formation of ET-1 (1-31) by TY-51469 proves that the 
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only chymase able to generate ET-1 (1-31) from Big ET-1 in mast cells is the mMCP-4. Similar 
reinforcing results were seen with peritoneal mast cells of mice mMCP-4 KO. 
Studies on human mast cells, on the other hand, have been limited by the rarity of functional 
human cell lines. In our experiments, we have used the LUVA cells which are an immortalized 
human mast cell line. The cells were derived from mononuclear cells of a donor with Aspirin 
exacerbated respiratory disease. The importance of these cells is that they are the first human 
mast cell line derived from a donor without a clonal mast cell disorder, as indicated by normal 
serum tryptase levels in the donor and the presence of metachromatic granules in those cells. In 
addition, they are the first human mast cell line expressing a functional chymase and they are 
maintained without stem cell factor and present high levels of c-kit and FcεRI (Laidlaw et al., 
2011). 
LUVA cells were utilized as a human model of mast cells. The human chymase extracted from 
these cells was able to cleave the fluorogenic substrate indicating that a chymotrypsin-like 
activity is present in this enzyme. Pre-incubation with TY-51469 was not sufficient to totally 
inhibit the chymotrypsin-like activity of the extract of LUVA cells. However the percentage 
inhibition was proportional to the concentration of TY-51469. The experiment was performed 
with concentrations of 10, 25 and 50 µM of TY-51469; an inhibition of around 60% was 
observed with the highest concentration of the inhibitor; indicating the possibility of the presence 
of other enzymes in the extract of LUVA cells that have a chymotrypsin-like activity. 
The human chymase extracted from LUVA cells was able to generate ET-1 (1-31) from its 
precursor. As we would have expected, pre-incubation with TY-51469 did not inhibit totally the 
production of ET-1 (1-31).  A concentration of 10 µM of the specific chymase inhibitor 
decreased the generation of ET-1 (1-31) by about 60%. This incomplete inhibition suggests the 
presence of other enzymes in LUVA cells responsible for the conversion of Big ET-1 into ET-1 
(1-31) such as cathepsin G (Caughey, 2007). 
Although the cleavage of the fluorogenic substrate and the conversion of Big ET-1 into ET-1 (1-
31) occurred with chymase extracted from LUVA cells, this enzymatic activity however was less 
efficient when compared to chymase extracted from murine peritoneal mast cells (Laidlaw et al., 
2011). 
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Our group has shown that the soluble fractions of organs (lungs, heart, aorta and kidneys) of WT 
mice were able to generate ET-1 (1-31) from its precursor. Pre-incubation with TY-51469 
inhibited totally the formation of ET-1 (1-31). This response was also seen in the soluble 
fractions of organs of mMCP-4 KO mice (Houde et al., 2013). These results indicate that 
although several enzymes with chymotrypsin-like activity are present in the soluble fractions of 
organs (as shown with the partial inhibition of cleavage of the fluorogenic substrate by TY-
51469 and/or with mMCP-4 mice), mMCP-4 is the only enzyme present in these fractions 
capable of processing Big ET-1 into ET-1 (1-31). Of note, no conversion to ET-1 was detected 
which can be explained by the fact that ECE and NEP are both membrane bound enzymes, 
contrary to mMCP-4 (Houde et al., 2013). 
With the same thought process, the soluble fractions of human aorta, taken from middle-aged 
brain-dead individuals with no histological signs of atherosclerosis, were able to generate ET-1 
(1-31) from Big ET-1; a process, contrarily to LUVA cells, totally abolished by TY-51469. This 
finding came in concurrence with the murine results of our laboratory and with the results of 
recombinant CMA1. Therefore these results demonstrate for the first time that ET-1 (1-31) 
production in the human blood vessels is chymase dependent. Recent studies have shown an 
increase in ET-1 (1-31) levels in atherosclerotic lesions in the aortic arch of hamsters which 
could indicate a yet to be determined role of chymase in human atherosclerosis hence a possible 
preventative method in arterial diseases (Mawatari et al., 2004). 
In another series of experiments, a characterization of the recombinant enzymes, rmMCP-4 and 
rCMA1 was done. The kinetic constants were determined for both enzymes using a fluorogenic 
substrate, Big ET-1 and Ang I as substrates.  
In the literature, the kinetic constants were determined for mMCP-4 purified from tissue 
extraction, using Ang I as a substrate and for recombinant human chymase using Ang I and Big 
ET-1 as a substrate. We wanted to compare our enzymes to the ones found in the literature. The 
hypothesis was that our recombinant enzymes have a chymotrypsin-like activity and is as 
efficacious in producing ET-1 (1-31) from Big ET-1 as Ang II from Ang I. 
Our results showed that the rmMCP-4 has similar affinities to Ang I and Big ET-1, with a 
slightly higher affinity for Ang I; a KM of 19.31 µM for Ang I versus a KM of 23.43 µM for Big 
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ET-1. These results did not concur with the literature, where it was shown that the affinity of the 
murine enzyme is about 34 times less (Caughey et al., 2000; Kunori et al., 2005). In addition the 
cleavage efficacy of the substrates was different. Our enzyme (rmMCP-4) has shown a higher 
efficacy in cleaving Ang I than Big ET-1. This was determined by the higher value of Kcat/KM 
7.7 x 10-3 µM-1.s-1 (for Ang I) compared to 2.189 x 10-3 µM-1.s-1 (for Big ET-1). The efficacy of 
our enzyme was higher than that reported in the literature for Ang I, as shown in table V.  
 
The difference observed when comparing our results to the literature may be attributed grossly to 
the nature of the enzymes utilized. The groups of Kumori and Caughey have used a chymase 
extracted and purified from Connective tissue Mast cells isolated from the skin of mice. This 
method compared to our recombinant method leads to a much less pure enzyme. The lack of 
purity of the enzymes implies that there are other enzymes or co-enzymes present in the purified 
extract that may affect the affinity of the enzyme to its substrate and/or affect the efficacy of the 
enzyme, rendering it either more or less efficacious. 
In addition, considering that some β-chymases are known to degrade Ang II by cleaving the Tyr 
4-Ile 5 bond and that mMCP-4 is able to generate and to degrade Ang II, the group of Caughey 
established the kinetic constants using the rate of degradation of Ang I rather than measuring the 
formation of the product Ang II (Lundequist et al., 2004) . Moreover the group of Kumori used 
Ang (5-10) instead of using Ang I as a substrate which may alter the results by either increasing 
or decreasing the affinity and the efficacy of the enzyme.  
 
Regarding CMA1, our results have shown a higher affinity to Big ET-1 than to Ang I; KM of 
12.55 µM and 37.53 µM respectively. These results show that our enzymes had a greater affinity 
for both substrates than what has been published in the literature. In addition, the affinity of 
CMA1 to the fluorogenic substrate was higher in our study than what has been published 
(Nakakubo et al., 2000). The group of Takai has published in 1999 a study characterizing the 
recombinant human chymase. The recombinant human chymase showed an affinity of 23.5 µM 
for Big ET-1 and 62.5 µM Ang I. Regarding the efficacy of the enzyme, the recombinant enzyme 
in Takai’s paper was more efficacious in cleaving Ang I, with a Kcat/KM of 0.86 µM
-1.s-1 whereas 
it was 1.8 x 10-4 µM-1.s-1 with our CMA1. This difference in affinity and efficacy can be 
attributed to the possible difference in the   purity of the enzymes or the experimental conditions 
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in which the experiments were done. Other studies have published kinetics constants of CMA1 
which were different than ours. However these studies (Takai et al., 1997; Nakakubo et al., 
2000) have used a purified chymase from tissues rather than a recombinant enzyme which 
explains the difference. 
In a comparison of the murine and human enzyme, we noticed that mMCP-4 is more efficient 
than CMA1 in processing Big ET-1 into ET-1 (1-31), as shown in table IV. In an attempt to 
explain this particular result, we performed in-silico studies using the X-ray structure of CMA1 
and a substrate analog as the template homology modeling of mMCP-4. Big ET-1 (28-35) was 
used as a substrate model. This analysis, as mentioned in our study (Semaan et al., 2015), 
suggested that the Tyr 31-Gly 32 (P1-P1’) bond of Big ET-1 would be closer to the active center 
of mMCP-4 then CMA1 which can explain the higher Kcat/Km value of the murine enzyme 
compares to the human one. It is important to mention, however, that the in-silico studies were 
performed using an octapeptide as a substrate whereas Big ET-1 is a peptide constituted of 38 
peptides. 
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Table IV. Enzyme Kinetics of rmMCP-4 and rCMA1 against Big ET-1 and Ang I 
 
  
 mMCP-4 CMA1 
 
Big ET-1 Ang I Big ET-1 Ang I 
KM (μM) 23.43 19.31 12.55 37.53 
Kcat (s
-1) 5.13 x 10-2 0.149 8.25 x 10-4 6.75 x 10-3 
Kcat/KM (μM
-1.s-1) 2.19 x 10-3 7.7 x 10-3 6.57 x 10-5 1.8 x 10-4 
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Table V. Enzyme Kinetics of mMCP-4 against Big ET-1 and Ang I compared to the 
literature 
 mMCP-4 
 
Big ET-1 Ang I Ang I 
 Caughey et al., 
2000 
Kumori et al., 
2005 
KM (μM) 23.43 19.31 698 673 
Kcat(s
-1) 5.13 x 10-2 0.149 3.1 0.33 
Kcat/KM(μM
-1.s-1) 2.19 x 10-3 7.7 x 10-3 4.4 x 10-3 4.9 x 10-4 
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In the third part of experiments, we wanted to confirm the role of chymase in the hypertensive 
response induced by administration of exogenous Big ET-1 in vivo. In the literature, several 
hemodynamic studies were performed on anesthetized mice. It is known that anesthetics can 
have different impacts on the heart rate and blood pressure. In the present study we have 
measured hemodynamic changes in conscious, freely moving, anesthesia-free mice. 
Several techniques are used to measure hemodynamic parameters in conscious mice: The fluid 
filled catheter system, the tail cuff, the millar probe and the telemetry probe implantation. Each 
technique has its pros and cons; we have used the telemetry probe implantation technique since it 
is less cumbersome on mice without jeopardizing results. After the implantation of the probe, the 
mice would feel some discomfort since they will be in a post-operative phase. On the other hand, 
once the post operative phase is over, the mice can move freely while their blood pressure is 
being measured in a highly sensitive manner over a long period of time, which is a big advantage 
of this technique. In addition, this technique can detect small variations in the blood pressure 
(Van Vliet et al., 2000; 2006). In order to help minimize the variation of blood pressure and heart 
rate related to pain or post operative discomfort, we have used Buprenorphine to control post-op 
pain in the first 24 hours and we started recording blood pressure and heart rate values 10 days 
after the surgery. Our group has shown that chymase (mMCP-4 specifically) is implicated in the 
hypertensive response induced by the administration of exogenous Big ET-1 in anesthetized 
mice (Simard et al,. 2009; Houde et al., 2013). As mentioned earlier, anesthetic agents have 
several effects on the heart rate and blood pressure which may be a confounding variable. In the 
present study we have started recording blood pressure and heart rate measurements in 
conscious, free moving mice, 10 days after the surgical implantation of the telemetry probe, 
allowing the mice to recover from surgical stress and for the anesthetic agent to be metabolized 
from the body. We have shown that exogenous Big ET-1 could increase MAP by 56.6 mmHg in 
WT mice; whereas its administration in mMCP-4 KO mice has increased MAP by 34.4 mmHg. 
This 40% difference in the increase in MAP can be attributed to the conversion of Big ET-1 to 
ET-1 (1-31) by mMCP-4 and subsequently to ET-1 by the ubiquitous NEP. This attribution was 
supported by the results of our group in 2013, when plasma levels of ET-1 (1-31) and  ET-1 
where shown to be higher in WT mice compared to mMCP-4 KO after administration of 
exogenous Big ET-1 (Houde et al., 2013). Furthermore ET-1 levels in plasma were similar in 
WT and mMCP-4 KO mice after administration of exogenous ET-1 (1-31) (Houde et al., 2013). 
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The effect of exogenous Big ET-1 on MAP was not observed with Ang I or Ang II. WT and 
mMCP-4 mice had the same increase in MAP with administration of exogenous Ang I or Ang II. 
This may be due to the abundance of ACE in vivo. 
There are few limitations to the present study. First regarding the recombinant enzymes, they 
were cloned as prochymases requiring activation by Cathepsin C and Heparin. We did not verify 
whether the solution that stops the activation process is able to inhibit/or enhance the activity of 
cathepsin C. Despite the fact that Cathepsin C is a DPPI, it might not be the ideal enzyme to 
activate our prochymases. Furthermore, the cathepsin C used was a murine one; so when it came 
to CMA1 activation, interspecies variations might have interfered in this activation. 
Second regarding MC, LUVA cells were not as efficacious as murine MC in the conversion of 
Big ET-1 into ET-1 (1-31) and this conversion was not completely inhibited TY-51469. These 
cells do not necessarily represent the ideal human MC but they are the best available model. 
Third, the in silico analysis was performed on an octapeptide rather than the whole Big ET-1 (38 
aa) not taking into account a possible interaction between the N or C terminal and/or the 
disulfide bridges of Big ET-1 with both chymases binding and/or catalytic sites. 
Fourth, regarding in vivo studies of MAP, external stimuli might have led to fluctuations in the 
blood pressure, however these external stimuli would exist in both groups studied (WT and 
mMCP-4 KO). To take into account these minimal stress related fluctuations, we have calculated 
areas under the curve to determine MAP. 
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Conclusion 
In conclusion, this work has shown an ability of mMCP-4 and CMA1 to generate ET-1 (1-31) 
from its precursor Big ET-1 in vitro. CMA1 extracted from healthy human aortas had a role in 
the production of ET-1 (1-31). Further studies are needed to establish its role in cardiovascular 
pathologies. For example, the use of aortas of hypertensive patients or atherosclerotic aortas with 
the comparison of the production of ET-1 (1-31) in these models is of high value.  
Chymase inhibitors are still in the preclinical level regarding cardiovascular diseases. Promising 
studies and results have shown a role for TY-51469 in preventing the development of 
hypertension, heart failure and bowel disease in rats (Palaniyandi et al., 2007; Takai et al., 2014; 
Liu et al., 2016). On the other hand, some chymase inhibitors are currently in clinical trials such 
as SUN 13834 for atopic dermatitis (Ogata et al., 2011) and BAY 1142524 for heart failure 
(phase II) (Zarin and Tse, 2016) . The success of BAY 1142524 can open the doors to clinical 
trials involving other cardiovascular diseases targeting both the angiotensin and the endothelin 
system.  
The hemodynamic studies suggested that although chymase is able to convert Ang I to Ang II in 
vitro, its significance is of less importance intravascularly in vivo which is not the case with the 
endothelin system where a KO of the chymase gene was associated with a lower increase in 
MAP after Big ET-1 administration. 
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